: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Liver Diseases

Free Subscription

Articles published in J Hepatol
Retrieve available abstracts of 1014 articles:
HTML format

Single Articles

July 2024

DI COLA S, D'Amico G, Merli M
Reply to "Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations ".
J Hepatol. 2024 Jul 11:S0168-8278(24)02353-5. doi: 10.1016/j.jhep.2024.
PubMed

KWON Y, Gottmann P, Wang S, Tissink J, et al
Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024 Jul 6:S0168-8278(24)02347-X. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
J Hepatol. 2024;81:e20-e21.
PubMed

CUSI K, Younossi Z, Roden M
From NAFLD to MASLD: Promise and pitfalls of a new definition.
J Hepatol. 2024;81:e18-e19.
PubMed

HE S, Luo Y, Ma W, Wang X, et al
Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis.
J Hepatol. 2024;81:135-148.
PubMed Abstract available

THORHAUGE KH, Semmler G, Johansen S, Lindvig KP, et al
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
J Hepatol. 2024;81:23-32.
PubMed Abstract available

June 2024

MENDOZA YP, Tsouka S, Semmler G, Seubnooch P, et al
Metabolic phenotyping of patients with Advanced Chronic Liver Disease for better characterization of Cirrhosis Regression.
J Hepatol. 2024 Jun 27:S0168-8278(24)02334-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ROONEY M, Duduskar SN, Ghait M, Reissing J, et al
Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection.
J Hepatol. 2024 Jun 25:S0168-8278(24)02325-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ZHANG Y, Chen J, Su S
The association between primary hypobetalipoproteinemia and hepatic Diseases: evidence from genetic studies.
J Hepatol. 2024 Jun 24:S0168-8278(24)02328-6. doi: 10.1016/j.jhep.2024.
PubMed

FUSTER-ANGLADA C, Mauro E, Ferrer-Fabrega J, Caballol B, et al
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.
J Hepatol. 2024 Jun 24:S0168-8278(24)02324-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

TARU V, Szabo G, Mehal W, Reiberger T, et al
Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation.
J Hepatol. 2024 Jun 20:S0168-8278(24)02322-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

PATMORE LA, Sonneveld MJ
Reply 'Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe'.
J Hepatol. 2024 Jun 11:S0168-8278(24)02311-0. doi: 10.1016/j.jhep.2024.
PubMed

SHAN D, Zhang G, Du Z
Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations.
J Hepatol. 2024 Jun 9:S0168-8278(24)02309-2. doi: 10.1016/j.jhep.2024.
PubMed

LAWITZ EJ, Fraessdorf M, Neff GW, Schattenberg JM, et al
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
J Hepatol. 2024 Jun 7:S0168-8278(24)02303-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

LI M, Bhoori S, Mehta N, Mazzaferro V, et al
Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
J Hepatol. 2024 Jun 5:S0168-8278(24)00423-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

COLAPIETRO F, Akpinar R, Pugliese N, Di Tommaso L, et al
Unexpected diagnosis in females with abnormal liver ultrasound.
J Hepatol. 2024;80:e243-e245.
PubMed

DUIJZER R, Boerrigter MM, Gevers TJG, Drenth JPH, et al
The pathophysiology of polycystic liver disease.
J Hepatol. 2024;80:981-983.
PubMed

BROUWERS MCGJ, Cassiman D
Rare monogenic causes of steatotic liver disease masquerading as MASLD.
J Hepatol. 2024;80:e252-e253.
PubMed

HASHIDA R, Nakano D, Kawaguchi M, Younossi ZM, et al
Changing from NAFLD to MASLD: The implications for health-related quality of life data.
J Hepatol. 2024;80:e249-e251.
PubMed

NORMAN JS, Mehta N
Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
J Hepatol. 2024;80:e273-e274.
PubMed

DAI H, Zhu C, Huai Q, Xu W, et al
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
J Hepatol. 2024;80:913-927.
PubMed Abstract available

WU XN, Wang MZ, Zhang N, Zhang W, et al
Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
J Hepatol. 2024;80:928-940.
PubMed Abstract available

ZOU Z, Liu X, Yu J, Ban T, et al
Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
J Hepatol. 2024;80:834-845.
PubMed Abstract available

CABIBBO G, Celsa C, Rimassa L, Torres F, et al
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice.
J Hepatol. 2024;80:957-966.
PubMed Abstract available

PANG Y, Aberg F, Chen Z, Li L, et al
Predicting risk of chronic liver disease in Chinese adults: External validation of the CLivD score.
J Hepatol. 2024;80:e264-e266.
PubMed

HE C, Lu D, Zheng S, Xu X, et al
Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
J Hepatol. 2024;80:e287-e288.
PubMed

ZHANG Y, Liu H, Sheng B, Tham YC, et al
Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard?
J Hepatol. 2024;80:e279-e281.
PubMed

VARGHESE J, Chapiro J
ChatGPT: The transformative influence of generative AI on science and healthcare.
J Hepatol. 2024;80:977-980.
PubMed Abstract available

May 2024

LAO Y, Cui X, Xu Z, Yan H, et al
Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.
J Hepatol. 2024 May 31:S0168-8278(24)00369-6. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

PATERNOSTRO R, Kwanten WJ, Hofer BS, Semmler G, et al
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
J Hepatol. 2024 May 30:S0168-8278(24)00368-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ROY A, Tewari A, Sonthalia N, Chand Ghoshal U, et al
Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
J Hepatol. 2024 May 24:S0168-8278(24)00363-5. doi: 10.1016/j.jhep.2024.
PubMed

DI COLA S, D'Amico G, Caraceni P, Schepis F, et al
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHAPUS F, Giraud G, Huchon P, Roda M, et al
Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes.
J Hepatol. 2024 May 21:S0168-8278(24)00351-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHEN J, Kaya NA, Zhang Y, Kendarsari RI, et al
A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and 'bad apple' effect on clinical trajectory.
J Hepatol. 2024 May 21:S0168-8278(24)00352-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

COLAPIETRO F, Lleo A
Reply: Incidence And Predictors Of Hepatocellular Carcinoma In Patients With Autoimmune Hepatitis?
J Hepatol. 2024 May 20:S0168-8278(24)00354-4. doi: 10.1016/j.jhep.2024.
PubMed

Erratum to "EASL Clinical Practice Guidelines on acute-on-chronic liver failure" [J Hepatol 79 (2023) 461-491].
J Hepatol. 2024 May 20:S0168-8278(24)00164-8. doi: 10.1016/j.jhep.2024.
PubMed

FRANCQUE S, Krag A, Shawcross DL, Zelber-Sagi S, et al
A Turning point in Hepatology? EASL Reflects on the First Approved Drug for MASH.
J Hepatol. 2024 May 16:S0168-8278(24)00340-4. doi: 10.1016/j.jhep.2024.
PubMed

ZHU CX, Yan K, Chen L, Huang RR, et al
Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma.
J Hepatol. 2024 May 15:S0168-8278(24)00342-8. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

NARDELLI S, Vizzutti F, Marra F, Schepis F, et al
Can we really advise a patient undergoing TIPS that the onset of episodic hepatic encephalopathy will not influence his/her survival?
J Hepatol. 2024 May 9:S0168-8278(24)00339-8. doi: 10.1016/j.jhep.2024.
PubMed

ZHANG Y, Xiao F, Xie R
Healthy volunteer bias for the role of genetic risk in dietary effects on hepatic steatosis, inflammation and fibrosis.
J Hepatol. 2024 May 9:S0168-8278(24)00335-0. doi: 10.1016/j.jhep.2024.
PubMed

YANG M, Zhang F, Liu K
Cirrhosis Decompensation: Clinical and Prognostic Analysis from a New Perspective.
J Hepatol. 2024 May 9:S0168-8278(24)00337-4. doi: 10.1016/j.jhep.2024.
PubMed

HARRISON SA, Rolph T, Knot M, Dubourg J, et al
FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.
J Hepatol. 2024 May 4:S0168-8278(24)00332-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

ZHU B, Guo Y, Lv S, Ling X, et al
Hepatic phenotypes of EFL1-related Shwachman-Diamond syndrome in a biopsy-validated study.
J Hepatol. 2024 May 3:S0168-8278(24)00328-3. doi: 10.1016/j.jhep.2024.
PubMed

FOUAD Y, Ghazinyan H, Alboraie M, Al Khatry M, et al
Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition.
J Hepatol. 2024;80:e194-e197.
PubMed

XIAO R, Tian Y, Zhang J, Li N, et al
Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
J Hepatol. 2024;80:792-804.
PubMed Abstract available

CHOLANKERIL G, Kanwal F
Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea".
J Hepatol. 2024;80:e218-e219.
PubMed

YOUNOSSI ZM, Paik JM, Stepanova M, Ong J, et al
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
J Hepatol. 2024;80:694-701.
PubMed Abstract available

WANG Z, Xie D, Li J, Zhai Z, et al
Molecular force-induced liberation of transforming growth factor-beta remodels the spleen for ectopic liver regeneration.
J Hepatol. 2024;80:753-763.
PubMed Abstract available

SUN Z, Liu M, Guo J, Wang S, et al
BMI status and its changes across adulthood in relation to all-cause mortality in metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024;80:e197-e199.
PubMed

XIAO MC, Jiang N, Chen LL, Liu F, et al
TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4alpha stability.
J Hepatol. 2024;80:778-791.
PubMed Abstract available

ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
J Hepatol. 2024;80:730-743.
PubMed Abstract available

XIAO H, Niu D, Zhang B
Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis.
J Hepatol. 2024;80:e207-e209.
PubMed

MA D, Li X
Methodological challenges in studying immune-suppressive neutrophils in HCC models.
J Hepatol. 2024;80:e215-e216.
PubMed

CIARDULLO S, Perseghin G
Steatotic liver disease phenotypes in the United States: The impact of alcohol consumption assessment.
J Hepatol. 2024;80:e203-e204.
PubMed

April 2024

YANG L, Niu K, Wang J, Shen W, et al
Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

TAN MY, Su JH
Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024.
PubMed

MCGETTIGAN B, Shah V
EVERY SHERIFF NEEDS A DEPUTY: TARGETING NON-PARENCHYMAL CELLS TO TREAT HEPATIC FIBROSIS.
J Hepatol. 2024 Apr 25:S0168-8278(24)00283-6. doi: 10.1016/j.jhep.2024.
PubMed

FU JT, Liu J, Wu WB, Chen YT, et al
Targeting EFHD2 Inhibits Interferon-gamma Signaling and Ameliorates Non-Alcoholic Steatohepatitis.
J Hepatol. 2024 Apr 24:S0168-8278(24)00277-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHEN K, Wang Y, Yang J, Kloting N, et al
EMC10 modulates hepatic ER stress and steatosis in an isoform specific manner.
J Hepatol. 2024 Apr 8:S0168-8278(24)00234-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

YIN K, Buttner M, Deligiannis IK, Strzelecki M, et al
Polyploidisation pleiotropically buffers ageing in hepatocytes.
J Hepatol. 2024 Apr 5:S0168-8278(24)00227-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHEN VL, Du X, Oliveri A, Chen Y, et al
Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.
J Hepatol. 2024 Apr 4:S0168-8278(24)00230-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MOGA L, Paradis V, Bruno O, Valla D, et al
Hepatomegaly in a patient with a history of acute myeloid leukemia.
J Hepatol. 2024;80:e139-e142.
PubMed

TREVISANI F, Vitale A, Kudo M, Kulik L, et al
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal.
J Hepatol. 2024;80:661-669.
PubMed Abstract available

WANG CW, Huang PC, Dai CY, Huang JF, et al
Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric label.
J Hepatol. 2024;80:e157-e159.
PubMed

SHIRI AM, Zhang T, Bedke T, Zazara DE, et al
IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction.
J Hepatol. 2024;80:634-644.
PubMed Abstract available

SUZUKI H, Tanaka T, Yamaguchi S, Miwa K, et al
Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD.
J Hepatol. 2024;80:e150-e151.
PubMed

CHEN J, Zhou H, Liu K
Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease.
J Hepatol. 2024;80:e143-e145.
PubMed

RETAT L, Webber L, Jepsen P, Martin A, et al
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study.
J Hepatol. 2024;80:543-552.
PubMed Abstract available

KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
J Hepatol. 2024;80:586-595.
PubMed Abstract available

YANG A, Zhu X, Zhang L, Ding Y, et al
Transitioning from NAFLD to MAFLD and MASLD: Consistent prevalence and risk factors in a Chinese cohort.
J Hepatol. 2024;80:e154-e155.
PubMed

March 2024

HEUSCHKEL MJ, Bach C, Meiss-Heydmann L, Gerges E, et al
Erratum to 'JAK1 promotes HDV replication and is a potential target for antiviral therapy' [J Hepatol 80 (2024) 220-231].
J Hepatol. 2024 Mar 30:S0168-8278(24)00165-X. doi: 10.1016/j.jhep.2024.
PubMed

D'AMICO G, Perricone G
Unaswered questions for non-acute (NAD) and acute (AD) decompensation in cirrhosis.
J Hepatol. 2024 Mar 26:S0168-8278(24)00210-1. doi: 10.1016/j.jhep.2024.
PubMed

CHAN SL, Ryoo BY, Mo F, Chan LL, et al
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
J Hepatol. 2024 Mar 26:S0168-8278(24)00216-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

STRANDBERG R, Jepsen P, Hagstrom H
Developing and Validating Clinical Prediction Models in Hepatology-an Overview for Clinicians.
J Hepatol. 2024 Mar 24:S0168-8278(24)00213-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

PASTA A, Pieri G, Plaz Torres MC, Trevisani F, et al
Hepatocellular carcinoma in patients with Autoimmune Hepatitis.
J Hepatol. 2024 Mar 23:S0168-8278(24)00208-3. doi: 10.1016/j.jhep.2024.
PubMed

NADIM MK, Kellum JA, Forni L, Francoz C, et al
Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting.
J Hepatol. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

YASHASWINI CN, Qin T, Bhattacharya D, Amor C, et al
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024 Mar 18:S0168-8278(24)00197-1. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

XU L, Zhang Y, Lin Z, Deng X, et al
FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
J Hepatol. 2024 Mar 18:S0168-8278(24)00199-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

MA AT, Sole C, Juanola A, Escude L, et al
Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

JACHS M, Sandmann L, Hartl L, Tergast T, et al
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHOI SH, Lee BM, Kim J, Kim DY, et al
Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study.
J Hepatol. 2024 Mar 9:S0168-8278(24)00154-5. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

HAXHE S, Baldin P, Trefois P, Havelange V, et al
Jaundice with severe leucocytosis.
J Hepatol. 2024;80:e103-e105.
PubMed

RUSSO FP, Francque SM, Shawcross DL, Krag AA, et al
Advocating for the implementation of the new nomenclature for steatotic liver disease: A call to action for the national associations.
J Hepatol. 2024;80:384-386.
PubMed

GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
J Hepatol. 2024;80:495-504.
PubMed Abstract available

DIAZ LA, Fuentes-Lopez E, Idalsoaga F, Ayares G, et al
Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes.
J Hepatol. 2024;80:409-418.
PubMed Abstract available

GE X, Desert R, Magdaleno F, Han H, et al
Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
J Hepatol. 2024;80:482-494.
PubMed Abstract available

YOUNOSSI ZM, Alqahtani SA, Alswat K, Yilmaz Y, et al
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
J Hepatol. 2024;80:419-430.
PubMed Abstract available

BOESCH M, Lindhorst A, Feio-Azevedo R, Brescia P, et al
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
J Hepatol. 2024;80:397-408.
PubMed Abstract available

BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
J Hepatol. 2024;80:467-481.
PubMed Abstract available

IRUZUBIETA P, Santos-Laso A, Arias-Loste MT, Calleja JL, et al
Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings.
J Hepatol. 2024;80:e121-e123.
PubMed

LEE E, Korf H, Vidal-Puig A
Reply to: "Liver-adipose tissue crosstalk in nonalcoholic fatty liver disease: the emerging role of remnant cholesterol": "BAT activation might improve NAFLD in patients, but this might require developing and/or maintaining functionally relevant level
J Hepatol. 2024;80:e112-e114.
PubMed

LARRUE H, Bureau C, D'Amico G
Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
J Hepatol. 2024;80:e109-e110.
PubMed

LIU Y, Chen M
Liver-adipose tissue crosstalk in non-alcoholic fatty liver disease: The emerging role of remnant cholesterol.
J Hepatol. 2024;80:e111-e112.
PubMed

February 2024

XIE P, Yu M, Zhang B, Yu Q, et al
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
J Hepatol. 2024 Feb 23:S0168-8278(24)00129-6. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

BLASZKIEWICZ J, Duncan SA
Use of stem cell-derived hepatocytes to model liver disease.
J Hepatol. 2024 Feb 15:S0168-8278(23)05306-0. doi: 10.1016/j.jhep.2023.
PubMed

CAON E, Martins M, Hodgetts H, Blanken L, et al
Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
J Hepatol. 2024 Feb 14:S0168-8278(24)00110-7. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

NARDELLI S, Riggio O, Marra F, Gioia S, et al
Response to "Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?".
J Hepatol. 2024 Feb 14:S0168-8278(24)00122-3. doi: 10.1016/j.jhep.2024.
PubMed

DE VILLE DE GOYET J
Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
PubMed

YANG H, Jang JW
Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!'.
J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024.
PubMed

ARTRU F, Reiberger T
One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
PubMed

ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

SOIN A, Lesurtel M, Clavien PA
To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
PubMed

HUANG CH, Tsai MH, Lin CY
Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
PubMed

LIU C, Guo C, Liu K
Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
PubMed

T R, J B
Endoscopic diagnosis and treatment for portal hypertension: not yet ready for clinical practice!
J Hepatol. 2024 Feb 6:S0168-8278(24)00120-X. doi: 10.1016/j.jhep.2024.
PubMed

WARGNY M, Goronflot T, Rimbert A, Boursier J, et al
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
J Hepatol. 2024 Feb 6:S0168-8278(24)00108-9. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

SILVA H, King JJ, Thorburn D, Luong TV, et al
A rare cause of liver fibrosis in an adult patient.
J Hepatol. 2024;80:e48-e50.
PubMed

ESLER WP, Cohen DE
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
J Hepatol. 2024;80:362-377.
PubMed Abstract available

ARORA U, Biswas S, Aggarwal S, Duseja A, et al
MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.
J Hepatol. 2024;80:e89-e91.
PubMed

DI SESSA A, Guarino S, Umano GR, Miraglia Del Giudice E, et al
MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
J Hepatol. 2024;80:e87-e89.
PubMed

PADILLA J, Osman NM, Bissig-Choisat B, Grimm SL, et al
Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
J Hepatol. 2024;80:282-292.
PubMed Abstract available

HE L, Zheng W, Qiu K, Kong W, et al
Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.
J Hepatol. 2024;80:e85-e87.
PubMed

KIM D, Wijarnpreecha K, Cholankeril G, Ahmed A, et al
Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.
J Hepatol. 2024;80:e79-e81.
PubMed

JEONG S
Nutrients associated with metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024;80:e81-e82.
PubMed

CHEN L, Tao X, Zeng M, Mi Y, et al
Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.
J Hepatol. 2024;80:e64-e66.
PubMed

SANAL MG
Is the change from NAFLD to MASLD driven by political correctness?
J Hepatol. 2024;80:e74-e76.
PubMed

HAGSTROM H, Vessby J, Ekstedt M, Shang Y, et al
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.
J Hepatol. 2024;80:e76-e77.
PubMed

PERAZZO H, Pacheco AG, Griep RH
Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort.
J Hepatol. 2024;80:e72-e74.
PubMed

LUO N, Zhang X, Huang J, Chen H, et al
Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
J Hepatol. 2024;80:e70-e71.
PubMed

EL-KASSAS M, Alswat K
Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time.
J Hepatol. 2024;80:e66-e68.
PubMed

JI H, Cheng S
Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters.
J Hepatol. 2024;80:e68-e69.
PubMed

SEMMLER G, Wernly B, Datz C
What's in a name? New nomenclature for steatotic liver disease - to be or not to be?
J Hepatol. 2024;80:e56-e58.
PubMed

SHIPMAN KE
Sample types and patient preparation required when adopting the new fatty liver disease nomenclature.
J Hepatol. 2024;80:e60-e61.
PubMed

DE A, Bhagat N, Mehta M, Taneja S, et al
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
J Hepatol. 2024;80:e61-e62.
PubMed

RATZIU V, Boursier J
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
J Hepatol. 2024;80:e51-e52.
PubMed

SONG SJ, Lai JC, Wong GL, Wong VW, et al
Can we use old NAFLD data under the new MASLD definition?
J Hepatol. 2024;80:e54-e56.
PubMed

LI M, Xie W
Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
J Hepatol. 2024;80:e53-e54.
PubMed

SCHNEIDER KM, Schneider CV
A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank.
J Hepatol. 2024;80:e58-e60.
PubMed

ZHANG Q, Wei T, Jin W, Yan L, et al
Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
J Hepatol. 2024;80:293-308.
PubMed Abstract available

LEI Z, Yu J, Wu Y, Shen J, et al
CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis.
J Hepatol. 2024;80:194-208.
PubMed Abstract available

January 2024

NING Z
An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
PubMed

CAMPION D, Caviglia GP, Alessandria C
Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
PubMed

NAYAGAM JS, Miquel R, Thompson RJ, Joshi D, et al
Genetic cholestasis in children and adults.
J Hepatol. 2024 Jan 30:S0168-8278(23)05305-9. doi: 10.1016/j.jhep.2023.
PubMed

TANG R, Li Y, Chen R, Ma X, et al
Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
PubMed

TABRIZIAN P, Abdelrahim M, Schwartz M
Immunotherapy and Transplantation for Hepatocellular Carcinoma.
J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
PubMed

ESPINOZA AF, Patel RH, Patel KR, Badachhape AA, et al
A Novel Treatment Strategy Utilizing Panobinostat for High-Risk and Treatment-Refractory Hepatoblastoma.
J Hepatol. 2024 Jan 17:S0168-8278(24)00040-0. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

CHAN LL, Mok K, Chan SL
Radiotherapy following Intrahepatic Progression on Immunotherapy in Advanced Hepatocellular Carcinoma.
J Hepatol. 2024 Jan 17:S0168-8278(24)00044-8. doi: 10.1016/j.jhep.2024.
PubMed

OSONOI S, Takebe T
Organoid-guided Precision Hepatology for Metabolic Liver Disease.
J Hepatol. 2024 Jan 16:S0168-8278(24)00038-2. doi: 10.1016/j.jhep.2024.
PubMed Abstract available

NAKANO M, Kawaguchi M, Kawaguchi T
Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia.
J Hepatol. 2024 Jan 13:S0168-8278(24)00037-0. doi: 10.1016/j.jhep.2023.
PubMed

JACHS M, Hartl L, Simbrunner B, Semmler G, et al
Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
J Hepatol. 2024 Jan 11:S0168-8278(24)00009-6. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SONG Q, Zhang X, Yu J
Reply to "Stop Using the Misidentified Cell Line - LO2 as a Human Hepatocyte".
J Hepatol. 2024 Jan 4:S0168-8278(24)00006-0. doi: 10.1016/j.jhep.2023.
PubMed

HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
PubMed

SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19].
J Hepatol. 2024 Jan 4:S0168-8278(23)05355-2. doi: 10.1016/j.jhep.2023.
PubMed

TERGAST TL, Maasoumy B
The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis.
J Hepatol. 2024 Jan 3:S0168-8278(24)00001-1. doi: 10.1016/j.jhep.2023.
PubMed

ZHENG C, Wang L, Zou T, Lian S, et al
Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells.
J Hepatol. 2024 Jan 3:S0168-8278(24)00004-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SALOMONE F, Pipitone RM, Longo M, Malvestiti F, et al
SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease.
J Hepatol. 2024;80:10-19.
PubMed Abstract available

BALCAR L, Mandorfer M, Hernandez-Gea V, Procopet B, et al
Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving beta-blockers+ligation to prevent re-bleeding.
J Hepatol. 2024;80:73-81.
PubMed Abstract available

THOMAIDES-BREARS H, Banerjee R, Banerjee A
Reply to: "Reassessing the causal relationship between liver diseases and cardiovascular outcomes" and "From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank".
J Hepatol. 2024;80:e24-e25.
PubMed

KAFFE E, Tisi A, Magkrioti C, Aidinis V, et al
Bioactive signalling lipids as drivers of chronic liver diseases.
J Hepatol. 2024;80:140-154.
PubMed Abstract available

XIANG X, Wei Y, Zhao K
Reassessing the causal relationship between liver diseases and cardiovascular outcomes.
J Hepatol. 2024;80:e20-e22.
PubMed

DIAZ-FONTENLA F, Caballero-Marcos A, Peligros I, Vicario Moreno JL, et al
Unusual early post-transplant hepatic dysfunction.
J Hepatol. 2024;80:e11-e13.
PubMed

December 2023

ZHANG F, Zhang M, Wang L, Zhuge Y, et al
Hepatic encephalopathy and survival after transjugular intrahepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?
J Hepatol. 2023 Dec 26:S0168-8278(23)05368-0. doi: 10.1016/j.jhep.2023.
PubMed

NORMAN JS, Mehta N
Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
PubMed

TONON M, D'Ambrosio R, Calvino V, Tosetti G, et al
A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.
J Hepatol. 2023 Dec 16:S0168-8278(23)05359-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

HAHN M, Herber A, Berg T, Seehofer D, et al
Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
PubMed

LEHRICH BM, Zhang J, Monga SP, Dhanasekaran R, et al
Battle of the Biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
J Hepatol. 2023 Dec 15:S0168-8278(23)05307-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

VUKOTIC R, Di Donato R, Bosch J, Andreone P, et al
Reply letter to the letter to the editor entitled: "5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?".
J Hepatol. 2023 Dec 12:S0168-8278(23)05302-3. doi: 10.1016/j.jhep.2023.
PubMed

NARDELLI S, Riggio O, Marra F, Gioia S, et al
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
J Hepatol. 2023 Dec 12:S0168-8278(23)05310-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

RATZIU V, Harrison SA, Hajji Y, Magnanensi J, et al
NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
J Hepatol. 2023 Dec 5:S0168-8278(23)05270-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

FAN W, Cao D, Yang B, Wang J, et al
Hepatic prohibitin 1 and methionine adenosyltransferase alpha1 defend against primary and secondary liver cancer metastasis.
J Hepatol. 2023 Dec 2:S0168-8278(23)05298-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ZANETTO A, Senzolo M, Pelizzaro F, Mescoli C, et al
A rare cause of painful hepatomegaly.
J Hepatol. 2023;79:e228-e230.
PubMed

Ending stigmatizing language in alcohol and liver disease: A liver societies' statement.
J Hepatol. 2023;79:1347-1348.
PubMed

HUTCHISON AL, Tavaglione F, Romeo S, Charlton M, et al
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
J Hepatol. 2023;79:1524-1541.
PubMed Abstract available

MOHR I, Poujois A, Ala A, Weiss KH, et al
Reply to: "Early neurological worsening in Wilson disease: The need for an evidence-based definition".
J Hepatol. 2023;79:e243.
PubMed

MENG Y, Ye F, Nie P, Zhao Q, et al
Immunosuppressive CD10(+)ALPL(+) neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.
J Hepatol. 2023;79:1435-1449.
PubMed Abstract available

PETERMANN-ROCHA F, Ho FK, Pell JP
Reply to: "Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations".
J Hepatol. 2023;79:e233-e234.
PubMed

SIMON TG, Roelstraete B, Hagstrom H, Loomba R, et al
Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
J Hepatol. 2023;79:1366-1373.
PubMed Abstract available

NEWSOME PN, Ambery P
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
J Hepatol. 2023;79:1557-1565.
PubMed Abstract available

LITWIN T, Czlonkowska A, Smolinski L
Early neurological worsening in Wilson disease: The need for an evidence-based definition.
J Hepatol. 2023;79:e241-e242.
PubMed

RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
J Hepatol. 2023;79:1542-1556.
PubMed Abstract available

LONG L, Zhou X
Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations.
J Hepatol. 2023;79:e232-e233.
PubMed

November 2023

COLASANTI O, Burm R, Huang HE, Riedl T, et al
Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
PubMed

KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
PubMed

BERASAIN C
When you eat and when you sleep matters: circadian dysfunction revealed as a direct hepatic carcinogen in a humanized mouse model.
J Hepatol. 2023 Nov 17:S0168-8278(23)05277-7. doi: 10.1016/j.jhep.2023.
PubMed

CELSA C, Cabibbo G, Am Fulgenzi C, Scheiner B, et al
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
J Hepatol. 2023 Nov 14:S0168-8278(23)05272-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SHAO T, Chen YL
Stop using the misidentified cell line - LO2 as a human hepatocyte.
J Hepatol. 2023 Nov 9:S0168-8278(23)05268-6. doi: 10.1016/j.jhep.2023.
PubMed

LIU J, Qian J, Yang Z, Zhou L, et al
Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
PubMed

GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

TELLEZ L, Payance A, Tjwa E, Del Cerro MJ, et al
EASL-ERN position paper on liver involvement in patients with Fontan-type circulation.
J Hepatol. 2023;79:1270-1301.
PubMed Abstract available

ROCA-FERNANDEZ A, Banerjee R, Thomaides-Brears H, Telford A, et al
Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
J Hepatol. 2023;79:1085-1095.
PubMed Abstract available

October 2023

BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976].
J Hepatol. 2023 Oct 31:S0168-8278(23)05179-6. doi: 10.1016/j.jhep.2023.
PubMed

BIBO W, Hao S, Yating W, Fucheng L, et al
Balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration.
J Hepatol. 2023 Oct 31:S0168-8278(23)05183-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

FERNANDEZ-GARZA LE
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
J Hepatol. 2023 Oct 25:S0168-8278(23)05228-5. doi: 10.1016/j.jhep.2023.
PubMed

MUCKE MM, Fong S, Foster GR, Lillicrap D, et al
Adeno-associated viruses for gene therapy - clinical implications and liver related complications, a guide for hepatologists.
J Hepatol. 2023 Oct 25:S0168-8278(23)05229-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

RATZIU V, Hompesch M, Petitjean M, Serdjebi C, et al
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.
J Hepatol. 2023 Oct 23:S0168-8278(23)05182-6. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CAMPION D, Ponzo P, Risso A, Caropreso P, et al
A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
J Hepatol. 2023 Oct 19:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

MAIWALL R, Rao Pasupuleti SS, Sarin SK
AUTHORS REPLY: High versus low target mean arterial pressure in septic shock in cirrhosis-A personalized TARGET-C approach may solve the conundrum!
J Hepatol. 2023 Oct 13:S0168-8278(23)05144-9. doi: 10.1016/j.jhep.2023.
PubMed

ZHANG L, Xu J, Zhou S, Yao F, et al
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.
J Hepatol. 2023 Oct 12:S0168-8278(23)05170-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CHEN X, Pan J, Zhu Y
Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored.
J Hepatol. 2023 Oct 11:S0168-8278(23)05163-2. doi: 10.1016/j.jhep.2023.
PubMed

KANG MG, Lee CH, Shen C, Kim JS, et al
Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea.
J Hepatol. 2023 Oct 10:S0168-8278(23)05166-8. doi: 10.1016/j.jhep.2023.
PubMed

SHA M, Cao J, Xia Q
Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
PubMed

CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
PubMed

GRONBAEK L, Gronbaek H
Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
PubMed

TRUSSONI CE, LaRusso NF
Macrophages make a difference in cholestatic liver diseases - but how?
J Hepatol. 2023 Oct 9:S0168-8278(23)05149-8. doi: 10.1016/j.jhep.2023.
PubMed

ABERG F, Savikko J, Eerola V, Nordin A, et al
High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
PubMed

COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LU W
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
PubMed

GROBA SR, Soehnlein O
DRANquilizing neutrophil function in chronic liver disease.
J Hepatol. 2023;79:885-887.
PubMed

ROMERO-GOMEZ M, Lawitz E, Shankar RR, Chaudhri E, et al
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
J Hepatol. 2023;79:888-897.
PubMed Abstract available

LI L, Wang Z, Jiang Y
Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again.
J Hepatol. 2023;79:e164-e165.
PubMed

GUO R, Xu X, Babcock SA, Zhang Y, et al
Retraction notice to "Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy" [J Hepatol 62 (3) (2015) 647-656].
J Hepatol. 2023;79:1072.
PubMed

September 2023

Corrigendum to "EASL Clinical Practice Guidelines on haemochromatosis" [J Hepatol 2022 (77) 479-502].
J Hepatol. 2023 Sep 26:S0168-8278(23)05088-2. doi: 10.1016/j.jhep.2023.
PubMed

Corrigendum to "EASL clinical practice guidelines on the management of hepatic encephalopathy" [J Hepatol 2022 (77) 807-824].
J Hepatol. 2023 Sep 26:S0168-8278(23)05090-0. doi: 10.1016/j.jhep.2023.
PubMed

Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].
J Hepatol. 2023 Sep 23:S0168-8278(23)05092-4. doi: 10.1016/j.jhep.2023.
PubMed

Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
PubMed

LALEMAN W, Vanderschueren E, Mehdi ZS, Wiest R, et al
Endoscopic procedures in HEPATOLOGY:CURRENT trends and new developments.
J Hepatol. 2023 Sep 18:S0168-8278(23)05101-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

Corrigendum to "EASL clinical practice guidelines on the management of cystic liver diseases" [J Hepatol (77) 1083-1108].
J Hepatol. 2023 Sep 17:S0168-8278(23)05089-4. doi: 10.1016/j.jhep.2023.
PubMed

CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
PubMed

NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CHEN X, Chen S, Pang J, Huang R, et al
Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux.
J Hepatol. 2023 Sep 5:S0168-8278(23)05077-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

WANG Q, Bu Q, Zhou H, Lu L, et al
Reply to?"Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis".
J Hepatol. 2023 Sep 4:S0168-8278(23)05076-6. doi: 10.1016/j.jhep.2023.
PubMed

EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy.
J Hepatol. 2023;79:768-828.
PubMed Abstract available

LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
A global research priority agenda to advance public health responses to fatty liver disease.
J Hepatol. 2023;79:618-634.
PubMed Abstract available

FUNDORA Y, Hessheimer AJ, Fondevila C
Reply to: "Reconstruction for complex portal vein thrombosis - Anatomical if possible".
J Hepatol. 2023;79:e131-e133.
PubMed

HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
J Hepatol. 2023;79:717-727.
PubMed Abstract available

BOURSIER J, Roux M, Sanyal AJ
Reply to: "Agile scores are a good predictor of liver-related events in patients with NAFLD".
J Hepatol. 2023;79:e128-e129.
PubMed

HARRISON SA, Ratziu V, Magnanensi J, Hajji Y, et al
NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: A prospective derivation and validation study.
J Hepatol. 2023;79:758-767.
PubMed Abstract available

WONG VW, Ekstedt M, Wong GL, Hagstrom H, et al
Changing epidemiology, global trends and implications for outcomes of NAFLD.
J Hepatol. 2023;79:842-852.
PubMed Abstract available

LIANG JX, Ampuero J, Niu H, Imajo K, et al
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
J Hepatol. 2023;79:592-604.
PubMed Abstract available

SHARMA N, Pandey S, Yadav M, Mathew B, et al
Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
J Hepatol. 2023;79:677-691.
PubMed Abstract available

DURAN M, Alfarah J, Hann A, Perera MTPR, et al
Reconstruction for complex portal vein thrombosis - Anatomical if possible.
J Hepatol. 2023;79:e129-e131.
PubMed

NAKATSUKA T, Tateishi R, Sato M, Fujishiro M, et al
Agile scores are a good predictor of liver-related events in patients with NAFLD.
J Hepatol. 2023;79:e126-e127.
PubMed

August 2023

CHEN R, Huang B, Lian M, Wei Y, et al
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
J Hepatol. 2023 Aug 31:S0168-8278(23)05069-9. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

EBRAHIMI F, Hagstrom H, Sun J, Bergman D, et al
Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study.
J Hepatol. 2023 Aug 28:S0168-8278(23)05071-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LIMOUSIN W, Laurent-Puig P, Ziol M, Ganne-Carrie N, et al
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
J Hepatol. 2023 Aug 28:S0168-8278(23)05070-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

BALLESTER MP, Carbonell-Asins JA, Balcar L, Reiberger T, et al
Reply to: Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
J Hepatol. 2023 Aug 23:S0168-8278(23)05068-7. doi: 10.1016/j.jhep.2023.
PubMed

CAI J, Wang J, Jiang C, Ye L, et al
Combined inhibition of surface CD51 and gamma-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.
J Hepatol. 2023 Aug 19:S0168-8278(23)05062-6. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

WAN YM, Wu HM, Huang SQ, Li HY, et al
A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B." (J Hepatol. 2023 May;78(5):926-936.).
J Hepatol. 2023 Aug 11:S0168-8278(23)05051-1. doi: 10.1016/j.jhep.2023.
PubMed

UPADHYAY KK, Du X, Chen Y, Buscher B, et al
A common variant that alters SUN1 degradation associates with hepatic steatosis and metabolic traits in multiple cohorts.
J Hepatol. 2023 Aug 9:S0168-8278(23)05049-3. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ZANETTO A, Pelizzaro F, Bellan E, Sbaraglia M, et al
Multiple hepatic cysts in an adult male.
J Hepatol. 2023;79:e64-e66.
PubMed

RATZIU V, Tacke F
At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASH.
J Hepatol. 2023;79:261-262.
PubMed

TSOCHATZIS EA
Screening for liver fibrosis - sequential non-invasive testing works best.
J Hepatol. 2023;79:263-265.
PubMed

KOTSILITI E, Leone V, Schuehle S, Govaere O, et al
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
J Hepatol. 2023;79:296-313.
PubMed Abstract available

FERNANDEZ-CHECA JC, Torres S, Garcia-Ruiz C
HILPDA, a new player in NASH-driven HCC, links hypoxia signaling with ceramide synthesis.
J Hepatol. 2023;79:269-272.
PubMed

SINGAL AG, Marrero J, Parikh ND
Reply to: "Correction for length bias reduces the mortality benefit from hepatocellular carcinoma surveillance".
J Hepatol. 2023;79:e90-e92.
PubMed

ROMA K, Mohammed S, Sieck B, Naik K, et al
Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
J Hepatol. 2023;79:581-584.
PubMed Abstract available

MOHR I, Pfeiffenberger J, Eker E, Merle U, et al
Neurological worsening in Wilson disease - clinical classification and outcome.
J Hepatol. 2023;79:321-328.
PubMed Abstract available

KJAERGAARD M, Lindvig KP, Thorhauge KH, Andersen P, et al
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
J Hepatol. 2023;79:277-286.
PubMed Abstract available

MEYER T, Galani S, Lopes A, Vogel A, et al
Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease.
J Hepatol. 2023;79:e73-e76.
PubMed

POVERO D, Chen Y, Johnson SM, McMahon CE, et al
HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
J Hepatol. 2023;79:378-393.
PubMed Abstract available

TACKE F, Puengel T, Loomba R, Friedman SL, et al
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
J Hepatol. 2023;79:552-566.
PubMed Abstract available

LE MH, Le DM, Baez TC, Wu Y, et al
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.
J Hepatol. 2023;79:287-295.
PubMed Abstract available

AYYALA-SOMAYAJULA D, Dodge JL, Farias A, Terrault N, et al
Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States.
J Hepatol. 2023;79:329-339.
PubMed Abstract available

YAHOO N, Dudek M, Knolle P, Heikenwalder M, et al
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
J Hepatol. 2023;79:538-551.
PubMed Abstract available

BAROUKI R, Samson M, Blanc EB, Colombo M, et al
The exposome and liver disease - how environmental factors affect liver health.
J Hepatol. 2023;79:492-505.
PubMed Abstract available

PENG J, Lu M, Peng Y, Tang X, et al
Global incidence of primary liver cancer by etiology among children, adolescents, and young adults.
J Hepatol. 2023;79:e92-e94.
PubMed

July 2023

PATIDAR KR, Belcher JM, Regner KR, St Hillien SA, et al
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
J Hepatol. 2023 Jul 28:S0168-8278(23)04990-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SANYAL AJ, Ratziu V, Loomba R, Anstee QM, et al
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

TAPPER EB, Bajaj JS
Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
J Hepatol. 2023 Jul 27:S0168-8278(23)05003-1. doi: 10.1016/j.jhep.2023.
PubMed

VUKOTIC R, Di Donato R, Roncarati G, Simoni P, et al
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
J Hepatol. 2023 Jul 21:S0168-8278(23)04940-1. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

KUTER DJ, Bonkovsky HL, Monroy S, Ross G, et al
Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
J Hepatol. 2023 Jul 19:S0168-8278(23)04933-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LU Y, Sun Q, Guan Q, Zhang Z, et al
The XOR-IDH3alpha axis controls macrophage polarization in hepatocellular carcinoma.
J Hepatol. 2023 Jul 18:S0168-8278(23)04984-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SONG Q, Zhang X, Liu W, Wei H, et al
Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
J Hepatol. 2023 Jul 15:S0168-8278(23)04981-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

GUAN MC, Ding Q, Zhu H
Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over one year ?
J Hepatol. 2023 Jul 4:S0168-8278(23)04937-1. doi: 10.1016/j.jhep.2023.
PubMed

AGARWAL B, Canizares RB, Saliba F, Ballester MP, et al
Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.
J Hepatol. 2023;79:79-92.
PubMed Abstract available

A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.
J Hepatol. 2023;79:4-5.
PubMed

CRAIG AJ, Silveira MAD
The role of ETV4 in HCC: How transcription factors can inform immunotherapy combination treatments.
J Hepatol. 2023;79:19-21.
PubMed

ROWE IA
Understanding the risks and benefits of policy action in NAFLD.
J Hepatol. 2023;79:22-24.
PubMed

BERAZA N
Ketohexokinase-C: The mechanistic link between dietary sugars and protein acetylation during liver steatosis.
J Hepatol. 2023;79:16-18.
PubMed

D'ARTISTA L, Moschopoulou AA, Barozzi I, Craig AJ, et al
MYC determines lineage commitment in KRAS-driven primary liver cancer development.
J Hepatol. 2023;79:141-149.
PubMed Abstract available

HACKSTEIN CP, Spitzer J, Symeonidis K, Horvatic H, et al
Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury.
J Hepatol. 2023;79:150-166.
PubMed Abstract available

VILLANUEVA C, Torres F, Tripathi D, Bosch J, et al
Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
J Hepatol. 2023;79:e23-e24.
PubMed

NAHON P, Trepo E
Reply to: "Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses".
J Hepatol. 2023;79:e35-e37.
PubMed

SCHEINER B, Balcar L, Lisman T, Mandorfer M, et al
Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'.
J Hepatol. 2023;79:e27-e28.
PubMed

ALLEN AM, Lazarus JV, Younossi ZM
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.
J Hepatol. 2023;79:209-217.
PubMed Abstract available

PONZIANI FR, Santopaolo F, Gasbarrini A, De Cristofaro R, et al
From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?
J Hepatol. 2023;79:e25-e27.
PubMed

RIDOLA L, Riggio O
Comment to: "TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.".
J Hepatol. 2023 Jul 1:S0168-8278(23)04938-3. doi: 10.1016/j.jhep.2023.
PubMed

LI Z, Hu Y, Zou B
The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 cirrhotic patients.
J Hepatol. 2023 Jul 1:S0168-8278(23)04935-8. doi: 10.1016/j.jhep.2023.
PubMed

June 2023

AGRAWAL D, Ariga KK
Target mean arterial pressure in critically ill cirrhotic patients with septic shock: More is not always better!
J Hepatol. 2023 Jun 29:S0168-8278(23)04931-0. doi: 10.1016/j.jhep.2023.
PubMed

YANG H, Kim JH, Han JW, Lee SK, et al
Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?'.
J Hepatol. 2023 Jun 27:S0168-8278(23)00425-7. doi: 10.1016/j.jhep.2023.
PubMed

CASSANO SANTOS U, Coelho de Souza MDG, Ferreira da Motta Rezende G
Selection of patients with portal hypertension and cirrhosis with real benefit of beta-blockers: still a current challenge.
J Hepatol. 2023 Jun 26:S0168-8278(23)00428-2. doi: 10.1016/j.jhep.2023.
PubMed

NAYAGAM JS, Masson S, Ferguson JW, Griffiths W, et al
Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?
J Hepatol. 2023 Jun 26:S0168-8278(23)00429-4. doi: 10.1016/j.jhep.2023.
PubMed

MINAMI T, Sato M, Toyoda H, Yasuda S, et al
Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ZHANG X, Sharma P, Maschmeyer P, Hu Y, et al
GARP on hepatic stellate cells is essential for the development of liver fibrosis.
J Hepatol. 2023 Jun 20:S0168-8278(23)00422-1. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

TAVABIE O
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
J Hepatol. 2023 Jun 12:S0168-8278(23)00413-0. doi: 10.1016/j.jhep.2023.
PubMed

BERTOLETTI A, Le Bert N, Tan AT, Boni C, et al
End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB, by Huang et al. J Hepatology 77, 42-54 (2022).
J Hepatol. 2023 Jun 10:S0168-8278(23)00408-7. doi: 10.1016/j.jhep.2023.
PubMed

LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
Natural history of NASH cirrhosis in liver transplant waitlist registrants.
J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CLAVERIA-CABELLO A, Herranz JM, Latasa MU, Arechederra M, et al
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
J Hepatol. 2023 Jun 9:S0168-8278(23)00405-1. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

FAN R, Chen L, Zhao S, Yang H, et al
Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ELKRIEF L, Ganne-Carrie N, Manceau H, Tanguy M, et al
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
J Hepatol. 2023 Jun 9:S0168-8278(23)00401-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LIU X, Wen X, Lu F
Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
J Hepatol. 2023 Jun 9:S0168-8278(23)00402-6. doi: 10.1016/j.jhep.2023.
PubMed

SENZOLO M, Garcia-Pagan JC
A major research gap: the use of anticoagulants in cirrhosis.
J Hepatol. 2023 Jun 9:S0168-8278(23)00407-5. doi: 10.1016/j.jhep.2023.
PubMed

FU W, Liu C, Li J
Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis.
J Hepatol. 2023 Jun 8:S0168-8278(23)00411-7. doi: 10.1016/j.jhep.2023.
PubMed

ALBILLOS A, Guerrero A, Tellez L
Reply to: "Anticoagulation to prevent disease progression in patients with cirrhosis".
J Hepatol. 2023 Jun 8:S0168-8278(23)00414-2. doi: 10.1016/j.jhep.2023.
PubMed

RAEVENS S, Fallon MB
Fingolimod as a sphingolipid modulator in hepatopulmonary syndrome: a critical review.
J Hepatol. 2023 Jun 8:S0168-8278(23)00406-3. doi: 10.1016/j.jhep.2023.
PubMed

FONDEVILA MF, Schnabl B
Intestinal clock modulates rhythmic hepatic metabolism.
J Hepatol. 2023 Jun 6:S0168-8278(23)00350-1. doi: 10.1016/j.jhep.2023.
PubMed

BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
J Hepatol. 2023 Jun 3:S0168-8278(23)00351-3. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SOIN A, Lesurtel M, Bhangui P, Cocchi L, et al
Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
J Hepatol. 2023;78:1124-1129.
PubMed Abstract available

BHAT M, Rabindranath M, Chara BS, Simonetto DA, et al
Artificial intelligence, machine learning, and deep learning in liver transplantation.
J Hepatol. 2023;78:1216-1233.
PubMed Abstract available

KASAHARA M, Hong JC, Dhawan A
Evaluation of living donors for hereditary liver disease (siblings, heterozygotes).
J Hepatol. 2023;78:1147-1156.
PubMed Abstract available

CLIFT AK, Hagness M, Lehmann K, Rosen CB, et al
Transplantation for metastatic liver disease.
J Hepatol. 2023;78:1137-1146.
PubMed Abstract available

ARTRU F, Goldberg D, Kamath PS
Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
J Hepatol. 2023;78:1118-1123.
PubMed Abstract available

TANDON P, Zanetto A, Piano S, Heimbach JK, et al
Liver transplantation in the patient with physical frailty.
J Hepatol. 2023;78:1105-1117.
PubMed Abstract available

TSOCHATZIS EA, Watt KD, VanWagner LB, Verna EC, et al
Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease.
J Hepatol. 2023;78:1089-1104.
PubMed Abstract available

BURRA P
The changing world of liver transplantation.
J Hepatol. 2023;78:1087-1088.
PubMed

May 2023

LALLOYER F, Mogilenko DA, Verrijken A, Haas JT, et al
Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis.
J Hepatol. 2023 May 23:S0168-8278(23)00341-0. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

HE F, Jiang H, Peng C, Wang T, et al
Hepatic glucuronyl C5-epimerase combats obesity by stabilizing GDF15.
J Hepatol. 2023 May 20:S0168-8278(23)00340-9. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

INNES H, Nahon P
Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.
J Hepatol. 2023 May 18:S0168-8278(23)00334-3. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LINDEN D, Romeo S
Mini-Review for Journal of HepatologyTherapeutic opportunities for the treatment of NASH with genetically validated targets.
J Hepatol. 2023 May 17:S0168-8278(23)00335-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SCHAEFFER S, Gupta B, Calatayud AL, Calderaro J, et al
RSK2 inactivation cooperates with AXIN1 inactivation or ss-catenin activation to promote hepatocarcinogenesis.
J Hepatol. 2023 May 16:S0168-8278(23)00333-1. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SHAWCROSS DL, Thabut D, Amodio P
Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
J Hepatol. 2023 May 11:S0168-8278(23)00327-6. doi: 10.1016/j.jhep.2023.
PubMed

ZHANG C, Ding WX
Caveats to link in vitro mechanistic mitophagy studies to the pathogenesis of non-alcoholic steatohepatitis.
J Hepatol. 2023 May 6:S0168-8278(23)00319-7. doi: 10.1016/j.jhep.2023.
PubMed

ASHRAF MU, De A, Rose S
Fingolimod, a sphingosine-1-phosphate agonist for the treatment of hepatopulmonary syndrome: Queries and concerns.
J Hepatol. 2023 May 3:S0168-8278(23)00315-X. doi: 10.1016/j.jhep.2023.
PubMed

LARRUE H, D'Amico G, Olivas P, Lv Y, et al
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
J Hepatol. 2023 May 2:S0168-8278(23)00314-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

YIN JL, Ala A, Miquel R
Histology - further raising the diagnostic bar in chronic liver disease.
J Hepatol. 2023;78:e162-e164.
PubMed

FUNDORA Y, Fuster-Anglada C, Bassaganyas C, Toapanta D, et al
An infrequent cause of spontaneous liver rupture.
J Hepatol. 2023;78:e160-e161.
PubMed

DI MARTINO V
Methotrexate-induced liver fibrosis: The end of a long-held belief.
J Hepatol. 2023;78:896-897.
PubMed

HARRISON SA, Thang C, Bolze S, Dewitt S, et al
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
J Hepatol. 2023;78:914-925.
PubMed Abstract available

LEE E, Korf H, Vidal-Puig A
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease.
J Hepatol. 2023;78:1048-1062.
PubMed Abstract available

ZHANG CJ, Meyer SR, O'Meara MJ, Huang S, et al
A human liver organoid screening platform for DILI risk prediction.
J Hepatol. 2023;78:998-1006.
PubMed Abstract available

AJMERA V, Loomba R
Reply to: "Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues".
J Hepatol. 2023;78:e168-e169.
PubMed

FALKEVALL A, Mehlem A, Folestad E, Ning FC, et al
Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
J Hepatol. 2023;78:901-913.
PubMed Abstract available

ATALLAH E, Grove JI, Crooks C, Burden-Teh E, et al
Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
J Hepatol. 2023;78:989-997.
PubMed Abstract available

SURIAL B, Ramirez Mena A, Roumet M, Limacher A, et al
External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
J Hepatol. 2023;78:947-957.
PubMed Abstract available

RATZIU V, Charlton M
Rational combination therapy for NASH: Insights from clinical trials and error.
J Hepatol. 2023;78:1073-1079.
PubMed Abstract available

BINET Q, Hermans MP, Lanthier N
Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues.
J Hepatol. 2023;78:e166-e167.
PubMed

ZHANG H, Peng Y, Tang X
Comment on: Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
J Hepatol. 2023;78:e177-e178.
PubMed

DALY AK, Bjornsson ES, Lucena MI, Andrade RJ, et al
Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort.
J Hepatol. 2023;78:e165-e166.
PubMed

April 2023

BERG T, Krag A
The future of hepatology - "The best way to predict your future is to create it".
J Hepatol. 2023 Apr 28:S0168-8278(23)00308-2. doi: 10.1016/j.jhep.2023.
PubMed

MAIWALL R, Rao Pasupuleti SS, Hidam AK, Kumar A, et al
A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock.
J Hepatol. 2023 Apr 21:S0168-8278(23)00229-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

PASSMAN AM, Haughey MJ, Carlotti E, Williams MJ, et al
Hepatocytes undergo punctuated expansion dynamics from a periportal stem cell niche in normal human liver.
J Hepatol. 2023 Apr 21:S0168-8278(23)00223-4. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

AGUILAR-BRAVO B, Arino S, Blaya D, Pose E, et al
Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming.
J Hepatol. 2023 Apr 21:S0168-8278(23)00236-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

GUO Z, Zhao Q, Jia Z, Huang C, et al
A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease.
J Hepatol. 2023 Apr 20:S0168-8278(23)00233-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

GRADY J, Clifford C, Treadwell MC, Parikh ND, et al
The Use of Fenofibrate for Intrahepatic Cholestasis of Pregnancy.
J Hepatol. 2023 Apr 19:S0168-8278(23)00237-4. doi: 10.1016/j.jhep.2023.
PubMed

YI H, Leng Q, Zhou J, Peng S, et al
Do open access articles have a citation advantage in Journal of Hepatology?
J Hepatol. 2023 Apr 19:S0168-8278(23)00238-6. doi: 10.1016/j.jhep.2023.
PubMed

ERIKSEN PL, Djernes L, Vilstrup H, Ott P, et al
Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments.
J Hepatol. 2023 Apr 13:S0168-8278(23)00220-9. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

JIN K, Shi Y, Zhang H, Zhangyuan G, et al
A TNFalpha/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis.
J Hepatol. 2023 Apr 9:S0168-8278(23)00215-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

VERMA N, Garg P, Bhardwaj A, Sarohi V, et al
Candida leucine aminopeptidase: a novel mycoprotein linked to invasive candidiasis and mortality in acutely decompensated cirrhosis.
J Hepatol. 2023 Apr 8:S0168-8278(23)00216-7. doi: 10.1016/j.jhep.2023.
PubMed

YEOH BS, Vijay-Kumar M
Gut microbiota lends a helping hand to nurse liver regeneration.
J Hepatol. 2023;78:681-683.
PubMed

LIU Y, Xun Z, Ma K, Liang S, et al
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
J Hepatol. 2023;78:770-782.
PubMed Abstract available

HADJIHAMBI A, Pellerin L
Reply to: "Is NAFLD a key driver of brain dysfunction?".
J Hepatol. 2023;78:e130-e131.
PubMed

RASMUSSEN DGK, Anstee QM, Torstenson R, Golding B, et al
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
J Hepatol. 2023;78:852-865.
PubMed Abstract available

LI C, He WQ
Global prediction of primary liver cancer incidences and mortality in 2040.
J Hepatol. 2023;78:e144-e146.
PubMed

WANG Y, Wang Y, Duan G, Yang H, et al
NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: A meta-analysis.
J Hepatol. 2023;78:e136-e139.
PubMed

SANDFORTH L, El-Agroudy NN, Birkenfeld AL
Is NAFLD a key driver of brain dysfunction?
J Hepatol. 2023;78:e129-e130.
PubMed

CHUNG DH, Zheng M, Bale AE, Vilarinho S, et al
Hepatology Genome Rounds: An interdisciplinary approach to integrate genomic data in clinical practice.
J Hepatol. 2023 Apr 1:S0168-8278(23)00208-8. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

March 2023

TOSETTI G, Degasperi E, Farina E, Primignani M, et al
Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
PubMed

PAIS R, Cariou B, Noureddin M, Francque S, et al
A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials.
J Hepatol. 2023 Mar 29:S0168-8278(23)00189-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

BAWEJA S, Kumari A, Negi P, Tomar A, et al
Hepatopulmonay syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
J Hepatol. 2023 Mar 28:S0168-8278(23)00192-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

HE F, Zhang P, Liu J, Wang R, et al
ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
J Hepatol. 2023 Mar 28:S0168-8278(23)00193-9. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LISMAN T, Bernal W, Luyendyk JP
Anticoagulation to prevent disease progression in patients with cirrhosis.
J Hepatol. 2023 Mar 28:S0168-8278(23)00198-8. doi: 10.1016/j.jhep.2023.
PubMed

JAGADISAN B, Dhawan A
Multidisciplinary approach and reactive immunosuppression for gene therapy related hepatotoxicity.
J Hepatol. 2023 Mar 28:S0168-8278(23)00197-6. doi: 10.1016/j.jhep.2023.
PubMed

EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.
J Hepatol. 2023 Mar 22:S0168-8278(23)00185-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

MANGINI C, Gagliardi R, Causin F, Angeli P, et al
Letter to the Editor: An isolated insular stroke mimics a bout of overt hepatic encephalopathy in a patient with cirrhosis.
J Hepatol. 2023 Mar 19:S0168-8278(23)00179-4. doi: 10.1016/j.jhep.2023.
PubMed

RIMASSA L, Finn RS, Sangro B
Combination immunotherapy for hepatocellular carcinoma.
J Hepatol. 2023 Mar 16:S0168-8278(23)00178-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(â˜†)" [J Hepatol (2020) 505-515].
J Hepatol. 2023 Mar 13:S0168-8278(23)00160-5. doi: 10.1016/j.jhep.2023.
PubMed

STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
Corrigendum to "Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease" [J Hepatol 77 (2022) 918-930].
J Hepatol. 2023 Mar 13:S0168-8278(23)00030-2. doi: 10.1016/j.jhep.2023.
PubMed

XIE M, Lin Z, Ji X, Luo X, et al
FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
J Hepatol. 2023 Mar 10:S0168-8278(23)00172-1. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
PubMed

VIOLI F, Pignatelli P, Cammisotto V
Platelet defetcts in cirrhosis: fact or fiction?
J Hepatol. 2023 Mar 8:S0168-8278(23)00173-3. doi: 10.1016/j.jhep.2023.
PubMed

TAN J, Fan W, Liu T, Zhu B, et al
TREM2(+) macrophages suppress CD8(+) T cell infiltration after transarterial chemoembolization in hepatocellular carcinoma.
J Hepatol. 2023 Mar 6:S0168-8278(23)00164-2. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

NOGUEIRAS R, Aspichueta P
Expanding the roles of the renin-angiotensin system: Drug-induced liver injury.
J Hepatol. 2023;78:457-459.
PubMed

GE J, Kim WR, Lai JC, Kwong AJ, et al
Response to: "Towards optimally replacing the current version of MELD".
J Hepatol. 2023;78:e100-e101.
PubMed

TROVATO FM, Zia R, Artru F, Mujib S, et al
Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure.
J Hepatol. 2023;78:558-573.
PubMed Abstract available

BANTEL H, Schulze-Osthoff K
Non-invasive tests for evaluating treatment response in NAFLD.
J Hepatol. 2023;78:e101-e102.
PubMed

KARTOUN U
Towards optimally replacing the current version of MELD.
J Hepatol. 2023;78:e98-e99.
PubMed

DURAND F, Kellum JA, Nadim MK
Fluid Resuscitation in Patients with Cirrhosis and Sepsis: A Multidisciplinary Perspective.
J Hepatol. 2023 Mar 1:S0168-8278(23)00113-7. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

LAPITZ A, Azkargorta M, Milkiewicz P, Olaizola P, et al
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma.
J Hepatol. 2023 Mar 1:S0168-8278(23)00159-9. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

February 2023

GUERRERO A, Campo LD, Piscaglia F, Scheiner B, et al
Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
J Hepatol. 2023 Feb 27:S0168-8278(23)00112-5. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

SINGAL AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, et al
International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance.
J Hepatol. 2023 Feb 26:S0168-8278(23)00111-3. doi: 10.1016/j.jhep.2023.
PubMed

ZENG L, Li X, Peng Z
Genetic variants improve hepatocellular carcinoma risk stratification, only in alcoholic cirrhosis patients?
J Hepatol. 2023 Feb 22:S0168-8278(23)00102-2. doi: 10.1016/j.jhep.2023.
PubMed

ROBINS CJG, Buchanan RM
Correction for length bias reduces the mortality benefit from Hepatocellular Carcinoma surveillance.
J Hepatol. 2023 Feb 21:S0168-8278(23)00104-6. doi: 10.1016/j.jhep.2023.
PubMed

HOARE M
Mouse models of hepatocyte biology - known unknowns.
J Hepatol. 2023 Feb 11:S0168-8278(23)00088-0. doi: 10.1016/j.jhep.2023.
PubMed

EBADI M, Burra P, Zanetto A, Montano-Loza AJ, et al
Current Treatment Strategies and Future Possibilities for Sarcopenia in Cirrhosis.
J Hepatol. 2023 Feb 10:S0168-8278(23)00090-9. doi: 10.1016/j.jhep.2023.
PubMed

FABRELLAS N, Kunzler-Heule P, Olofson A, Jack K, et al
Nursing Care For Patients With Cirrhosis.
J Hepatol. 2023 Feb 6:S0168-8278(23)00082-X. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

YUEN VW, Chiu DK, Law CT, Cheu JW, et al
Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
J Hepatol. 2023;78:376-389.
PubMed Abstract available

KISHORE SB, Lewindon P, Noble C, Balouch F, et al
Enoxaparin is safe and effective for restoring and preserving forward portal venous flow in children with end-stage liver disease.
J Hepatol. 2023;78:e57-e59.
PubMed

LI Z, Zhang B, Li J, Tao Z, et al
Assessing causal relationship between non-alcoholic fatty liver disease and risk of atrial fibrillation.
J Hepatol. 2023;78:e63-e65.
PubMed

STAUFER K, Mangal B, Trauner M
Detection of unreported alcohol consumption in fatty liver disease.
J Hepatol. 2023;78:e67-e69.
PubMed

ROEHLEN N, Muller M, Nehme Z, Crouchet E, et al
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
J Hepatol. 2023;78:343-355.
PubMed Abstract available

FROMENTY B, Roden M
Mitochondrial alterations in fatty liver diseases.
J Hepatol. 2023;78:415-429.
PubMed Abstract available

BERASAIN C, Arechederra M, Argemi J, Fernandez-Barrena MG, et al
Loss of liver function in chronic liver disease: An identity crisis.
J Hepatol. 2023;78:401-414.
PubMed Abstract available

PARADIS V, Zucman-Rossi J
Pathogenesis of primary liver carcinomas.
J Hepatol. 2023;78:448-449.
PubMed

HAGSTROM H, Ekstedt M
Considerations in the search for under-reported alcohol consumption in NAFLD.
J Hepatol. 2023;78:e66-e67.
PubMed

CARLSON S, Vaz K, Peterson A
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?
J Hepatol. 2023 Feb 1:S0168-8278(23)00074-0. doi: 10.1016/j.jhep.2023.
PubMed

January 2023

SPOSITO C, Cucchetti A, Mazzaferro V
Survival Benefit Of Lymphadenectomy For Intrahepatic Cholangiocarcinoma: It Might Be Gold Even If It Does Not Glitter.
J Hepatol. 2023 Jan 31:S0168-8278(23)00073-9. doi: 10.1016/j.jhep.2023.
PubMed

ZANETTO A, Northup P, Roberts L, Senzolo M, et al
Hemostasis in cirrhosis: understanding destabilising factors during acute decompensation.
J Hepatol. 2023 Jan 25:S0168-8278(23)00022-3. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

MAY S, Muller M, Livingstone CR, Skalka GL, et al
Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration.
J Hepatol. 2023 Jan 23:S0168-8278(23)00021-1. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

FUNDORA Y, Hessheimer AJ, Del Prete L, Maroni L, et al
Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis.
J Hepatol. 2023 Jan 20:S0168-8278(23)00018-1. doi: 10.1016/j.jhep.2023.
PubMed Abstract available

YIN Y, Sichler A, Ecker J, Laschinger M, et al
Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis.
J Hepatol. 2023 Jan 18:S0168-8278(23)00009-0. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

JI R, Chen J, Xie Y, Dou X, et al
Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
J Hepatol. 2023 Jan 18:S0168-8278(23)00015-6. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

TAO L, Yang G, Sun T, Tao J, et al
Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1.
J Hepatol. 2023 Jan 17:S0168-8278(23)00013-2. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

SANDMANN L, Tergast TL, Wedemeyer H, Deterding K, et al
3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.
J Hepatol. 2023 Jan 17:S0168-8278(23)00010-7. doi: 10.1016/j.jhep.2023.
PubMed

JI D, Tan L, Yang Y
Reply to "Biejia-Ruangan compound and incidence of hepatocellular carcinoma".
J Hepatol. 2023 Jan 13:S0168-8278(23)00008-9. doi: 10.1016/j.jhep.2023.
PubMed

CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581].
J Hepatol. 2023 Jan 11:S0168-8278(22)03321-9. doi: 10.1016/j.jhep.2022.
PubMed

POVERO D
Novel oncometabolites and metabolic checkpoints involved in hepatocellular carcinoma development.
J Hepatol. 2023 Jan 11:S0168-8278(23)00001-6. doi: 10.1016/j.jhep.2023.
PubMed

MAGYAR CTJ, Beldi G, Banz V
Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma - Letter to the editor.
J Hepatol. 2023 Jan 5:S0168-8278(22)03474-2. doi: 10.1016/j.jhep.2022.
PubMed

CHEN L, Fan Z, Zhao Y, Yang H, et al
Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses.
J Hepatol. 2023 Jan 3:S0168-8278(22)03476-6. doi: 10.1016/j.jhep.2022.
PubMed

ANOLLI MP, Degasperi E, Allweiss L, Sangiovanni A, et al
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

MOULTON CD, Staite E, Winkley K, Heneghan MA, et al
The association between liver fibrosis and cognitive impairment in type 2 diabetes.
J Hepatol. 2023;78:e18-e20.
PubMed

SHEN Y, Chen H, Wu SD, Jiang W, et al
Accuracy of transient elastography in assessing fibrosis at diagnosis in individuals with autoimmune liver disease.
J Hepatol. 2023;78:e33-e34.
PubMed

BOETTLER T, Krag A, Berg T
Reply to: "Depiction of alcohol-related liver disease in the EASL International Liver Congress".
J Hepatol. 2023;78:e38-e39.
PubMed

TRIPATHI M, Kumar Singh B, Yen PM
Reply to: "B vitamins for NASH: Use methylcobalamin, not cyanocobalamin".
J Hepatol. 2023;78:e35-e36.
PubMed

CARDINALE V, Carpino G, Overi D, Safarikia S, et al
Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential.
J Hepatol. 2023;78:165-179.
PubMed Abstract available

ABERG F, Byrne CD, Pirola CJ, Mannisto V, et al
Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease.
J Hepatol. 2023;78:191-206.
PubMed Abstract available

PARK J, Zhao Y, Zhang F, Zhang S, et al
IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
J Hepatol. 2023;78:45-56.
PubMed Abstract available

SPENCE JD
B vitamins for NASH: Use methylcobalamin, not cyanocobalamin.
J Hepatol. 2023;78:e34-e35.
PubMed

MA T, Yu X, Sun M
Relationship between non-alcoholic fatty liver disease and atrial fibrillation: Assessment of latest evidence.
J Hepatol. 2023;78:e31-e33.
PubMed

HADJIHAMBI A, Konstantinou C, Klohs J, Monsorno K, et al
Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction.
J Hepatol. 2023;78:180-190.
PubMed Abstract available

GAO X, Lv F, He X, Zhao Y, et al
Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
J Hepatol. 2023;78:16-27.
PubMed Abstract available

GOODHEART RH, Ayonrinde OT
Depiction of alcohol-related liver disease in the EASL International Liver Congress.
J Hepatol. 2023;78:e36-e38.
PubMed

December 2022

MCPHAIL MJ, Patel VC, Carter B
Carvedilol in patients with compensated cirrhosis: the ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices.
J Hepatol. 2022 Dec 31:S0168-8278(22)03471-7. doi: 10.1016/j.jhep.2022.
PubMed

INNES H
Genetic data not yet a "game-changer" for predicting individualised hepatocellular carcinoma risk.
J Hepatol. 2022 Dec 30:S0168-8278(22)03467-5. doi: 10.1016/j.jhep.2022.
PubMed

LIN H, Cheuk-Yan Yiu D, Chin S, Liu K, et al
Metformin in patients with hepatocellular carcinoma receiving immunotherapy.
J Hepatol. 2022 Dec 23:S0168-8278(22)03463-8. doi: 10.1016/j.jhep.2022.
PubMed

CHOI WM, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, et al
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis.
J Hepatol. 2022 Dec 23:S0168-8278(22)03459-6. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

KOERKAMP BG, Clavien PA, Polak WG
Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes?
J Hepatol. 2022 Dec 23:S0168-8278(22)03327-X. doi: 10.1016/j.jhep.2022.
PubMed

LEE BP, Dodge JL, Terrault NA
Liver Transplant for Alcohol-Associated Liver Disease Continues to Rise 2-Years into the COVID-19 Pandemic Especially Among Young Adults.
J Hepatol. 2022 Dec 22:S0168-8278(22)03460-2. doi: 10.1016/j.jhep.2022.
PubMed

HARTMANN P, Schnabl B
Fungal infections and the fungal microbiome in hepatobiliary disorders.
J Hepatol. 2022 Dec 21:S0168-8278(22)03415-8. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

WEI CY, Zhu MX, Zhang PF, Huang XY, et al
Corrigendum to: "PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].
J Hepatol. 2022 Dec 21:S0168-8278(22)03295-0. doi: 10.1016/j.jhep.2022.
PubMed

ALBILLOS A, Krag A
Beta-blockers in the era of precision medicine in patients with cirrhosis.
J Hepatol. 2022 Dec 15:S0168-8278(22)03330-X. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

SANYAL AJ, Williams SA, Lavine JE, Tetri B, et al
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease.
J Hepatol. 2022 Dec 14:S0168-8278(22)03326-8. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

KENDRE G, Murugesan K, Brummer T, Segatto O, et al
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
J Hepatol. 2022 Dec 14:S0168-8278(22)03328-1. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

MAK LY, Gane E, Schwabe C, Yoon KT, et al
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
J Hepatol. 2022 Dec 10:S0168-8278(22)03320-7. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

BAIGES A, Reverter JC, Garcia Pagan JC
Reply to "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis".
J Hepatol. 2022 Dec 9:S0168-8278(22)03322-0. doi: 10.1016/j.jhep.2022.
PubMed

LI Z, Hu Y, Li Q
More efforts to explore the association between cirrhosis and COVID-19 mortality, and the association between NAFLD and severe COVID-19.
J Hepatol. 2022 Dec 8:S0168-8278(22)03319-0. doi: 10.1016/j.jhep.2022.
PubMed

KOH JY, Rha MS, Choi SJ, Lee HS, et al
Erratum to 'Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner' [J Hepatol 77 (2022) 1059-1070].
J Hepatol. 2022 Dec 2:S0168-8278(22)03141-5. doi: 10.1016/j.jhep.2022.
PubMed

RUMGAY H, Arnold M, Ferlay J, Lesi O, et al
Global burden of primary liver cancer in 2020 and predictions to 2040.
J Hepatol. 2022;77:1598-1606.
PubMed Abstract available

MITTEN EK, Baffy G
Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease.
J Hepatol. 2022;77:1642-1656.
PubMed Abstract available

PAFILI K, Kahl S, Mastrototaro L, Strassburger K, et al
Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease.
J Hepatol. 2022;77:1504-1514.
PubMed Abstract available

MENDEZ-SANCHEZ N, Pal SC
New terms for fatty liver disease other than MAFLD: Time for a reality check.
J Hepatol. 2022;77:1716-1717.
PubMed

BRANDEL V, Schimek V, Gober S, Hammond T, et al
Hepatectomy-induced apoptotic extracellular vesicles stimulate neutrophils to secrete regenerative growth factors.
J Hepatol. 2022;77:1619-1630.
PubMed Abstract available

TIAN C, Min X, Zhao Y, Wang Y, et al
MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM.
J Hepatol. 2022;77:1491-1503.
PubMed Abstract available

KIM BK, Tamaki N, Imajo K, Yoneda M, et al
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
J Hepatol. 2022;77:1482-1490.
PubMed Abstract available

EUROPEAN ASSOCIATION FOR THE S
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.
PubMed

YIP TC, Wong VW, Lai MS, Lai JC, et al
Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

November 2022

SUN J, Ding J, Shen Q, Wang X, et al
Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
J Hepatol. 2022 Nov 30:S0168-8278(22)03311-6. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

THABUT D, Kudo M
Treatment of portal hypertension in patients with HCC at the era of Baveno VII.
J Hepatol. 2022 Nov 29:S0168-8278(22)03313-X. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

MIESBACH W, Foster GR, Peyvandi F
Liver-Related Aspects of Gene Therapy for Haemophilia: Call to Action for Collaboration between Haematologists and Hepatologists.
J Hepatol. 2022 Nov 24:S0168-8278(22)03307-4. doi: 10.1016/j.jhep.2022.
PubMed

NAHON P, Bamba-Funck J, Layese R, Trepo E, et al
Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.
J Hepatol. 2022 Nov 22:S0168-8278(22)03294-9. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

LOUVET A, Bourcier V, Archambeaud I, d'Alteroche L, et al
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
J Hepatol. 2022 Nov 21:S0168-8278(22)03304-9. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

AJMERA V, Cepin S, Tesfai K, Hofflich H, et al
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

CHOI SJ, Choi SH, Kim DW, Kwag M, et al
Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
J Hepatol. 2022 Nov 16:S0168-8278(22)03297-4. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

CHOLANKERIL G, Kramer JR, Chu J, Yu X, et al
Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
J Hepatol. 2022 Nov 16:S0168-8278(22)03299-8. doi: 10.1016/j.jhep.2022.
PubMed Abstract available

LUO L, Yao X, Yang W
Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
PubMed

BAJAJ JS
Albumin for Liver-Brain Outcome Improvement Across Different Situations in Cirrhosis.
J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03298.
PubMed

SANYAL AJ, Foucquier J, Younossi ZM, Harrison SA, et al
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
J Hepatol. 2022 Nov 11. pii: S0168-8278(22)03293.
PubMed Abstract available

CHEN S, Lu Z, Jia H, Yang B, et al
Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice.
J Hepatol. 2022 Nov 9. pii: S0168-8278(22)03285.
PubMed Abstract available

SHEN W, Middleton MS, Cunha GM, Delgado TI, et al
Changes in abdominal adipose tissue depots accessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
J Hepatol. 2022 Nov 8. pii: S0168-8278(22)03284.
PubMed Abstract available

ZHANG X, Song J, Zhang Y, Wen B, et al
Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis.
J Hepatol. 2022 Nov 7. pii: S0168-8278(22)03287.
PubMed Abstract available

ARTZNER T, Belli LS, Faitot F, Jalan R, et al
Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
PubMed

RATZIU V, Harrison SA, Loustaud-Ratti V, Bureau C, et al
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03160.
PubMed Abstract available

TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
Reply to 'Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients'.
J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03162.
PubMed

VAN KLEEF LA, Kavousi M, de Knegt RJ
Reply to: "Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues".
J Hepatol. 2022;77:1467-1468.
PubMed

PETERMANN-ROCHA F, Ho FK, Pell JP
Reply to: "Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants".
J Hepatol. 2022;77:1454-1455.
PubMed

ENGELMANN C, Habtesion A, Hassan M, Kerbert AJ, et al
Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
J Hepatol. 2022;77:1325-1338.
PubMed Abstract available

ALLEN AM, Therneau TM, Ahmed OT, Gidener T, et al
Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
J Hepatol. 2022;77:1237-1245.
PubMed Abstract available

TRIPATHI M, Singh BK, Zhou J, Tikno K, et al
Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.
J Hepatol. 2022;77:1246-1255.
PubMed Abstract available

JIN B, Du S, Yang H
HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.
J Hepatol. 2022;77:1469-1470.
PubMed

TSAI WC, Yu ML, Dai CY
Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues.
J Hepatol. 2022;77:1466-1467.
PubMed

NAOUMOV NV, Brees D, Loeffler J, Chng E, et al
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
J Hepatol. 2022;77:1399-1409.
PubMed Abstract available

HENDRIKX T, Porsch F, Kiss MG, Rajcic D, et al
Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH.
J Hepatol. 2022;77:1373-1385.
PubMed Abstract available

DIAO YK, Kong QY, Yang T
HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?
J Hepatol. 2022;77:1468-1469.
PubMed

CHEN L, Fan Z, Lv G
Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
J Hepatol. 2022;77:1453-1454.
PubMed

TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
Reply to 'The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?'
J Hepatol. 2022 Nov 1. pii: S0168-8278(22)03161.
PubMed

October 2022

SPOSITO C, Ratti F, Cucchetti A, Ardito F, et al
Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma.
J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03158.
PubMed Abstract available

NOUREDDIN M, Harrison SA
NASH Cirrhosis Trials And Major Adverse Liver Outcomes: Big Data Needed.
J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03159.
PubMed

CABIBBO G, Bruix J
Radiological endpoints as surrogates for survival benefit in Hepatocellular Carcinoma trials: all that glitters is not gold.
J Hepatol. 2022 Oct 30. pii: S0168-8278(22)03155.
PubMed

LI B, Hong C, Fan Z, Cai S, et al
Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acutely decompensated cirrhosis.
J Hepatol. 2022 Oct 26. pii: S0168-8278(22)03144.
PubMed Abstract available

PRYKE R, Guha IN
Time to focus chronic liver diseases back into the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.
J Hepatol. 2022 Oct 22. pii: S0168-8278(22)03146.
PubMed Abstract available

NEVENS F, Trauner M, Manns MP
Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.
J Hepatol. 2022 Oct 19. pii: S0168-8278(22)03143.
PubMed Abstract available

LI T, Lu Z
Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
J Hepatol. 2022 Oct 11. pii: S0168-8278(22)03136.
PubMed

PERICAS JM, Tacke F, Anstee QM, Di Prospero NA, et al
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.
J Hepatol. 2022 Oct 7. pii: S0168-8278(22)03131.
PubMed Abstract available

TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
PubMed Abstract available

BITTENCOURT PL, Oliveira CP, Codes L, Ferraz MLG, et al
Internet search engines and social media are improving awareness on non-alcoholic fatty liver disease in Brazil.
J Hepatol. 2022;77:1217-1219.
PubMed

PEISELER M, Schwabe R, Hampe J, Kubes P, et al
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
J Hepatol. 2022;77:1136-1160.
PubMed Abstract available

EASL Clinical Practice Guidelines on the management of cystic liver diseases.
J Hepatol. 2022;77:1083-1108.
PubMed Abstract available

DE GOTTARDI A, Sempoux C, Berzigotti A
Porto-sinusoidal vascular disorder.
J Hepatol. 2022;77:1124-1135.
PubMed Abstract available

VAN KLEEF LA, Lu Z, Arfan Ikram M, de Groot NMS, et al
Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study.
J Hepatol. 2022;77:931-938.
PubMed Abstract available

STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
J Hepatol. 2022;77:918-930.
PubMed Abstract available

BASTATI N, Beer L, Ba-Ssalamah A, Poetter-Lang S, et al
Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD.
J Hepatol. 2022;77:1005-1013.
PubMed Abstract available

September 2022

ELFEKI MA, Singal AK
The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?
J Hepatol. 2022 Sep 30. pii: S0168-8278(22)03125.
PubMed

WANG Y, Hu M, Yang H
Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.
J Hepatol. 2022 Sep 27. pii: S0168-8278(22)03122.
PubMed

REINIS J, Petrenko O, Simbrunner B, Hofer BS, et al
Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03119.
PubMed Abstract available

FAGAN A, Gavis EA, Gallagher ML, Mousel T, et al
A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study.
J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03116.
PubMed Abstract available

RIDOLA L, Riggio O
Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients.
J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03112.
PubMed

ARECHEDERRA M, Fernandez-Barrena MG
Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
PubMed

ZANETTO A, Pelizzaro F, Campello E, Bulato C, et al
Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.
J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03110.
PubMed Abstract available

KUDO M, Finn RS, Qin S, Han KH, et al
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03111.
PubMed Abstract available

MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
PubMed

MAIWALL R, Deshmukh A, Sarin SK
Reply to: "Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]".
J Hepatol. 2022 Sep 13. pii: S0168-8278(22)03069.
PubMed

PARIKH ND, Tayob N, Singal AG
Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
J Hepatol. 2022 Sep 8. pii: S0168-8278(22)03067.
PubMed Abstract available

KAZANKOV K, Novelli S, Chatterjee DA, Phillips A, et al
Evaluation of CirrhoCare(R) - A digital-health solution for home management of patients with cirrhosis.
J Hepatol. 2022 Sep 7. pii: S0168-8278(22)03066.
PubMed Abstract available

PATERNOSTRO R, Kwanten WJ, Reiberger T
Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease.
J Hepatol. 2022 Sep 4. pii: S0168-8278(22)03062.
PubMed

SEMMLER G, Lens S, Meyer EL, Baiges A, et al
Non-invasive tests for clinically significant portal hypertension after HCV cure.
J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
PubMed Abstract available

LUJAMBIO A, Sarobe P
Metformin keeps CD8(+) T cells active and moving in NASH-HCC immunotherapy.
J Hepatol. 2022;77:593-595.
PubMed

MANDORFER M, Scheiner B, Lisman T
On coagulation in advanced chronic liver disease and the origin of freshwater eels.
J Hepatol. 2022;77:886-887.
PubMed

LANGER MM, Eickelmann C, Kleinbongard P, Lange CM, et al
Impaired mitochondrial complex IV respiration in peripheral blood mononuclear cells discriminates acute-on-chronic liver failure from acute decompensation.
J Hepatol. 2022;77:874-876.
PubMed

CHEN ZX, Liu SY, Tong XM
Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?
J Hepatol. 2022;77:892-893.
PubMed

GREUTER T, Yaqoob U, Gan C, Jalan-Sakrikar N, et al
Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo.
J Hepatol. 2022;77:723-734.
PubMed Abstract available

CHOI SE, Hwang Y, Lee SJ, Jung H, et al
Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice.
J Hepatol. 2022;77:735-747.
PubMed Abstract available

BASELLI GA, Jamialahmadi O, Pelusi S, Ciociola E, et al
Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
J Hepatol. 2022;77:596-606.
PubMed Abstract available

WABITSCH S, McCallen JD, Kamenyeva O, Ruf B, et al
Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD.
J Hepatol. 2022;77:748-760.
PubMed Abstract available

XIE J, Lu L, Chen Y, Xu L, et al
A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults.
J Hepatol. 2022;77:877-879.
PubMed

BAIGES A, Procopet B, Silva-Junior G, Llop E, et al
Incidence and factors predictive of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03054.
PubMed Abstract available

YANG H, Bae SH, Jang JW
Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
PubMed

August 2022

WHITFIELD JB, Morgan TR, Seth D
Reply to: External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
J Hepatol. 2022 Aug 30. pii: S0168-8278(22)03055.
PubMed

WANG Q, Zhao H, Deng Y, Zheng H, et al
Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
PubMed Abstract available

ROSENBERG N, Van Haele M, Lanton T, Brashi N, et al
Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
J Hepatol. 2022 Aug 18. pii: S0168-8278(22)02995.
PubMed Abstract available

SALEM R, Greten TF
Interventional radiology meets immuno-oncology for hepatocellular carcinoma.
J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03003.
PubMed Abstract available

LABENZ C, Arslanow A, Lammert F, Galle PR, et al
Reply to: "an individualized cirrhosis screening strategy might be more cost-effective in the general population".
J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03006.
PubMed

CALDERARO J, Di Tommaso L, Maille P, Beaufrere A, et al
Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02983.
PubMed Abstract available

BASELLI G, Romeo S, Valenti L
Reply to: "Lack of hepatic autophagy promotes severity of liver injury but not steatosis": ATG7 genetic variants behave as fatty liver disease progression modifiers.
J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02992.
PubMed

KENNEDY L, Carpino G, Owen T, Ceci L, et al
Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02999.
PubMed Abstract available

JI D, Chen Y, Bi J, Shang Q, et al
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
PubMed Abstract available

JOHN BV, Ferreira RD, Doshi A, Kaplan DE, et al
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis.
J Hepatol. 2022 Aug 16. pii: S0168-8278(22)03002.
PubMed Abstract available

BAILEY AL, Diamond MS
Hepatopathology of flaviviruses.
J Hepatol. 2022 Aug 15. pii: S0168-8278(22)00339.
PubMed

AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
PubMed

BOWLUS CL, Levy C, Hirschfield GM
Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
PubMed

DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
PubMed Abstract available

GEHRING AJ, MacParland SA
Intrahepatic T cells with NK-like properties: expanding the repertoire of lymphocytes sensitive to bystander activation.
J Hepatol. 2022 Aug 12. pii: S0168-8278(22)02985.
PubMed

ALAZAWI W
Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
J Hepatol. 2022;77:290-292.
PubMed

EASL Clinical Practice Guidelines on haemochromatosis.
J Hepatol. 2022;77:479-502.
PubMed Abstract available

SCHOMERUS G, Leonhard A, Manthey J, Morris J, et al
The stigma of alcohol-related liver disease and its impact on healthcare.
J Hepatol. 2022;77:516-524.
PubMed Abstract available

BLACK SM, Zhang Z, Han Y, Zeng C, et al
Reply to: "Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis".
J Hepatol. 2022;77:562-563.
PubMed

BUGIANESI E, Petta S
NAFLD/NASH.
J Hepatol. 2022;77:549-550.
PubMed

BJORNSSON HK, Bjornsson ES
Reply to: "Can azathioprine prevent infliximab-induced liver injury?"
J Hepatol. 2022;77:555-556.
PubMed

ROWE IA, D'Amico G
Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction.
J Hepatol. 2022;77:293-295.
PubMed

JAESCHKE H, Umbaugh DS
Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis.
J Hepatol. 2022;77:560-562.
PubMed

ABERG F, Luukkonen PK, But A, Salomaa V, et al
Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score.
J Hepatol. 2022;77:302-311.
PubMed Abstract available

MEUNIER L, Malezieux E, Bozon A, Meszaros M, et al
Can azathioprine prevent infliximab-induced liver injury?
J Hepatol. 2022;77:553-555.
PubMed

July 2022

TRANAH TH, Ballester MP, Carbonell-Asins JA, Ampuero J, et al
Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
J Hepatol. 2022 Jul 21. pii: S0168-8278(22)02947.
PubMed Abstract available

MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
PubMed

NELL P, Kattler K, Feuerborn D, Hellwig B, et al
Identification of an FXR-modulated liver-intestine hybrid state in iPSC-derived hepatocyte-like cells.
J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02943.
PubMed Abstract available

LIU SY, Yuan C, Tong XM
Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
PubMed

ZHAO S, Liao X, Fan R
An individualized cirrhosis screening strategy might be more cost-effective in the general population.
J Hepatol. 2022 Jul 14. pii: S0168-8278(22)02937.
PubMed

MAIMONE S, Tripodi VF, Mazzeo AT
Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
J Hepatol. 2022 Jul 7. pii: S0168-8278(22)02926.
PubMed

FONTANELLAS A, Avila MA
Hydroxymethylbilane synthase (aka porphobilinogen deaminase): a novel metabolic tumor suppressor gene in hepatocellular carcinoma.
J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02921.
PubMed

BARCENA-VARELA M
Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.
J Hepatol. 2022;77:9-11.
PubMed

GUO B, Zhou J, Zhao X
Reply to: "Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"".
J Hepatol. 2022;77:260-262.
PubMed

YU M, Chen Z, Zhou Q, Zhang B, et al
PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
J Hepatol. 2022;77:140-151.
PubMed Abstract available

MARTI-AGUADO D, Clemente-Sanchez A, Bataller R
Cigarette smoking and liver diseases.
J Hepatol. 2022;77:191-205.
PubMed Abstract available

CHEN YS, Hung YM, Wei JC
Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease".
J Hepatol. 2022;77:259-260.
PubMed

MENDEZ-SANCHEZ N, Maris-Gil S, Alonso-Rivera CG
Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
J Hepatol. 2022;77:249.
PubMed

June 2022

VERMA AK, Sharma A, Subramaniyam N, Gandhi CR, et al
Augmenter of liver regeneration: mitochondrial function and steatohepatitis.
J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00413.
PubMed Abstract available

CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
PubMed Abstract available

HUANG B, Lyu Z, Qian Q, Chen Y, et al
NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
PubMed Abstract available

ALVISI G, Termanini A, Soldani C, Portale F, et al
Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
PubMed Abstract available

JEPSEN P, Reeves H
Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.
PubMed

BEAUFRERE A, Vilgrain V, Paradis V
Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al.: "Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies".
J Hepatol. 2022 Jun 19. pii: S0168-8278(22)00374.
PubMed

SCHLEGEL A, Porte RJ, Dutkowski P
Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
PubMed

BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
PubMed Abstract available

LURZ E, Lenz D, Bufler P, Fichtner A, et al
Letter to the editor - A peditatric hepatologists' perspective.
J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
PubMed

JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.
PubMed

SALEM R, Tselikas L, De Baere T
Interventional treatment of hepatocellular carcinoma.
J Hepatol. 2022 Jun 12. pii: S0168-8278(22)00229.
PubMed

TANG Y, Chen Y, Chen HN
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
PubMed

EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
J Hepatol. 2022 Jun 7. pii: S0168-8278(22)00346.
PubMed

GRAVELY AK, Vibert E, Sapisochin G
Surgical treatment of intrahepatic cholangiocarcinoma.
J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
PubMed

ANSTEE QM, Castera L, Loomba R
Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
J Hepatol. 2022;76:1362-1378.
PubMed Abstract available

CALDERARO J, Seraphin TP, Luedde T, Simon TG, et al
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.
J Hepatol. 2022;76:1348-1361.
PubMed Abstract available

CARACENI P, O'Brien A, Gines P
Long-term albumin treatment in patients with cirrhosis and ascites.
J Hepatol. 2022;76:1306-1317.
PubMed Abstract available

LISMAN T, Caldwell SH, Intagliata NM
Haemostatic alterations and management of haemostasis in patients with cirrhosis.
J Hepatol. 2022;76:1291-1305.
PubMed Abstract available

TERRAULT NA, Dufour JF, Schwabe RF, Wong VW, et al
Breakthroughs in hepatology.
J Hepatol. 2022;76:1247-1248.
PubMed

GARDIN A, Remih K, Gonzales E, Andersson ER, et al
Modern therapeutic approaches to liver-related disorders.
J Hepatol. 2022;76:1392-1409.
PubMed Abstract available

BAJAJ JS, Ng SC, Schnabl B
Promises of microbiome-based therapies.
J Hepatol. 2022;76:1379-1391.
PubMed Abstract available

GE J, Kim WR, Lai JC, Kwong AJ, et al
"Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
J Hepatol. 2022;76:1318-1329.
PubMed Abstract available

RATZIU V, Francque S, Sanyal A
Breakthroughs in therapies for NASH and remaining challenges.
J Hepatol. 2022;76:1263-1278.
PubMed Abstract available

May 2022

VILLANUEVA C, Torres F, Sarin SK, Shah HA, et al
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
J Hepatol. 2022 May 31. pii: S0168-8278(22)00336.
PubMed Abstract available

MOLINA L, Zhu J, Trepo E, Bayard Q, et al
Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.
J Hepatol. 2022 May 27. pii: S0168-8278(22)00333.
PubMed Abstract available

KOH JY, Rha MS, Choi SJ, Lee HS, et al
Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner.
J Hepatol. 2022 May 26. pii: S0168-8278(22)00335.
PubMed Abstract available

POURIKI S, Alexopoulos T, Vasilieva L, Vrioni G, et al
Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis.
J Hepatol. 2022 May 25. pii: S0168-8278(22)00328.
PubMed

YOO S, Kim JY, Lim YS, Han S, et al
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
PubMed Abstract available

DING WX, Ni HM, Waguri S, Komatsu M, et al
Lack of Hepatic Autophagy Promotes Severity of Liver Injury but Not Steatosis.
J Hepatol. 2022 May 25. pii: S0168-8278(22)00330.
PubMed

CHU CM, Liaw YF
Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
PubMed

HUSAIN A, Chiu YT, Oi-Lin Ng I
EFNAs are functional predictors for overall survival of hepatocellular carcinoma patients.
J Hepatol. 2022 May 20. pii: S0168-8278(22)00317.
PubMed

MISHRA AK, Singh SP
Seladelpar in patients with primary biliary cholangitis: Need a closer look!
J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
PubMed

GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
PubMed

SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
PubMed

SUMAZIN P, Peters TL, Sarabia SF, Kim HR, et al
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
J Hepatol. 2022 May 13. pii: S0168-8278(22)00275.
PubMed Abstract available

YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
PubMed

WANG KC, Sun LY, Wang MD
Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
PubMed

SCHEINER B, Pinter M
Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
J Hepatol. 2022 May 5. pii: S0168-8278(22)00266.
PubMed

DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
J Hepatol. 2022 May 5. pii: S0168-8278(22)00265.
PubMed

SEMMLER G, Mandorfer M
Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
PubMed

BHAGAT N, Verma N, Singh V
HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
PubMed

WANG YZ
Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
J Hepatol. 2022 May 4. pii: S0168-8278(22)00246.
PubMed

DONNELLY MC, Stableforth W, Krag A, Reuben A, et al
The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary.
J Hepatol. 2022;76:995-1000.
PubMed

REIG M, Bruix J
Reply to: "Correspondence on the ".
J Hepatol. 2022;76:1240-1241.
PubMed

PETERMANN-ROCHA F, Gray SR, Forrest E, Welsh P, et al
Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
J Hepatol. 2022;76:1021-1029.
PubMed Abstract available

AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
Value of liver biopsy in the diagnosis of drug-induced liver injury.
J Hepatol. 2022;76:1070-1078.
PubMed Abstract available

LEE BP, Cullaro G, Vosooghi A, Yao F, et al
Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
J Hepatol. 2022;76:1122-1126.
PubMed Abstract available

SCHEINER B, Balcar L, Nussbaumer RJ, Weinzierl J, et al
Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
J Hepatol. 2022;76:1090-1099.
PubMed Abstract available

XU X, Lau WY, Yang T
The updated BCLC staging system needs further refinement: A surgeon's perspective.
J Hepatol. 2022;76:1239-1240.
PubMed

MARJOT T, Ray DW, Tomlinson JW
Is it time for chronopharmacology in NASH?
J Hepatol. 2022;76:1215-1224.
PubMed Abstract available

MAHMUD N, Chapin S, Goldberg DS, Reddy KR, et al
Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
J Hepatol. 2022;76:1100-1108.
PubMed Abstract available

BOURSIER J, Hagstrom H, Ekstedt M, Moreau C, et al
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
J Hepatol. 2022;76:1013-1020.
PubMed Abstract available

BERRY P, Kotha S
Improving end of life care in liver disease.
J Hepatol. 2022;76:1225-1226.
PubMed

ELHENCE A, Shalimar
Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: Clear as day or still in fog?
J Hepatol. 2022;76:1236-1237.
PubMed

GOVAERE O, Petersen SK, Martinez-Lopez N, Wouters J, et al
Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
J Hepatol. 2022;76:1001-1012.
PubMed Abstract available

April 2022

TANTAI X, Yeo YH, Wang J, Ji F, et al
Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
PubMed

FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
PubMed

LIU C, Zha Z, Zhou C, Chen Y, et al
Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
J Hepatol. 2022 Apr 27. pii: S0168-8278(22)00240.
PubMed

LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
PubMed Abstract available

MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
PubMed Abstract available

ZHANGYUAN G
Is beta-catenin mutation in murine hepatocytes sufficient to induce liver tumorigenesis?
J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00242.
PubMed

JIANG X, Fulte S, Deng F, Chen S, et al
Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis.
J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00245.
PubMed Abstract available

ALKHOURI N, Herring R, Kabler H, Kayali Z, et al
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00235.
PubMed Abstract available

DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].
J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00198.
PubMed

CHUAH S, Lee J, Song Y, Kim HD, et al
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00233.
PubMed Abstract available

LI C, Ouyang W, Yang T
The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.
J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00228.
PubMed

CHAPIRO J
Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma.
J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00227.
PubMed

YANG H, Bae SH, Nam H, Lee HL, et al
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
PubMed Abstract available

RUSSO FP, Vigano M, Stock P, Ferrarese A, et al
HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist.
J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00175.
PubMed Abstract available

YANG T, Poenisch M, Khanal R, Hu Q, et al
Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00197.
PubMed

TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].
J Hepatol. 2022 Apr 6. pii: S0168-8278(22)00196.
PubMed

DEMIR M, Lang S, Hartmann P, Duan Y, et al
The fecal mycobiome in non-alcoholic fatty liver disease.
J Hepatol. 2022;76:788-799.
PubMed Abstract available

MEHAL WZ, Schwabe RF
A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease.
J Hepatol. 2022;76:765-767.
PubMed

CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
J Hepatol. 2022;76:832-840.
PubMed Abstract available

BYRNE CD, Newsome PN, Noureddin M
Why are there no strategies for NAFLD?
J Hepatol. 2022;76:763-764.
PubMed

LAZARUS JV, Mark HE, Villota-Rivas M, Palayew A, et al
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
J Hepatol. 2022;76:771-780.
PubMed Abstract available

FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
J Hepatol. 2022;76:946-958.
PubMed Abstract available

NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
J Hepatol. 2022;76:781-787.
PubMed Abstract available

SCORLETTI E, Carr RM
A new perspective on NAFLD: Focusing on lipid droplets.
J Hepatol. 2022;76:934-945.
PubMed Abstract available

March 2022

BARSCH M, Salie H, Schlaak AE, Zhang Z, et al
T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00180.
PubMed Abstract available

WANG S, Wu Q, Chen T, Su R, et al
Blocking CD47 promotes anti-tumor immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.
J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00179.
PubMed Abstract available

LI D, Yi C, Huang H, Li J, et al
Hepatocyte specific depletion of Nnmt protects the mice from non-alcoholic steatohepatitis.
J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00191.
PubMed

BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
PubMed Abstract available

ZANETTO A, Campello E, Bulato C, Gavasso S, et al
Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
J Hepatol. 2022 Mar 29. pii: S0168-8278(22)00177.
PubMed Abstract available

JALAN R, Rose CF
Heretical thoughts into Hepatic Encephalopathy.
J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00183.
PubMed Abstract available

BEAULANT A, Dia M, Pillot B, Chauvin MA, et al
Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis.
J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00185.
PubMed Abstract available

LIN P, Yang H
EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients.
J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00176.
PubMed

TAPPER EB, Essien UR, Zhao Z, Ufere NN, et al
Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00116.
PubMed Abstract available

MAGYAR CTJ, Beldi G, Banz V
Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations.
J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00186.
PubMed

TANTAI X, Yeo YH, Wang J, Ji F, et al
Reply to: "Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis".
J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00182.
PubMed

YANG Y, Ouyang J, Zhou Y, Zhou J, et al
The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.
J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00188.
PubMed

XIONG J, Tian Y
Evaluating sarcopenia in cirrhosis patients: the role of muscle function.
J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00190.
PubMed

TRIPODI A
Cirrhosis. What are all those factor VIII and protein C for?
J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00189.
PubMed

SCHWARZ C, Chromy D, Bangert C, Schwarz M, et al
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.
J Hepatol. 2022 Mar 16. pii: S0168-8278(22)00172.
PubMed

SUN R, Zhang Z, Bao R, Guo X, et al
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
PubMed Abstract available

WANG Q, Zhou H, Bu Q, Wei S, et al
Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00140.
PubMed Abstract available

NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
PubMed

WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00117.
PubMed

TORGERSEN J, Taddei TH, Lo Re V 3rd
Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
PubMed

SINGH SP, Jindal A
Association of rectal colonisation by MDROs with new infection in cirrhosis.
J Hepatol. 2022 Mar 9. pii: S0168-8278(22)00135.
PubMed

SUN X, Wu J, Liu L, Chen Y, et al
Transcriptional switch of hepatocytes initiates macrophage recruitment and T cell suppression in endotoxemia.
J Hepatol. 2022 Mar 8. pii: S0168-8278(22)00136.
PubMed Abstract available

INNES H, Morling JR, Buch S, Hamill V, et al
Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
J Hepatol. 2022 Mar 7. pii: S0168-8278(22)00129.
PubMed Abstract available

XU L, Yang Y, Wen Y, Jeong JM, et al
Hepatic recruitment of eosinophils and their protective function during acute liver injury.
J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
PubMed Abstract available

LOESCH R, Caruso S, Paradis V, Godard C, et al
Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
J Hepatol. 2022 Mar 4. pii: S0168-8278(22)00130.
PubMed Abstract available

EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.
J Hepatol. 2022 Mar 2. pii: S0168-8278(21)02033.
PubMed Abstract available

SPELIOTES EK, George J
Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
J Hepatol. 2022;76:498-500.
PubMed

DING WX, Sancho-Bru P
SOX9 acts downstream of YAP to decide liver cell fate and tumor types.
J Hepatol. 2022;76:503-505.
PubMed

MARTINEZ J, Hernandez-Gea V, Albillos A
Reply to: "Potential novel approaches to prevent the risk of infection in patients with variceal bleeding".
J Hepatol. 2022;76:752-753.
PubMed

SHALTOUT I, Alkandari H, Fouad Y, Hamed AE, et al
Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease.
J Hepatol. 2022;76:739-740.
PubMed

DEPRET F, Bouam S, Schwarzinger M, Mallet V, et al
Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database".
J Hepatol. 2022;76:744-747.
PubMed

EL-SHABRAWI M, Memon I, Attia D, El-Koofy NM, et al
The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease.
J Hepatol. 2022;76:738-739.
PubMed

LIU D, Zhang Q, Bai P, Zhao J, et al
Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease.
J Hepatol. 2022;76:740-742.
PubMed

WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
J Hepatol. 2022;76:749-751.
PubMed

ALABSAWY E, Shalimar, Jalan R
Potential novel approaches to prevent the risk of infection in patients with variceal bleeding.
J Hepatol. 2022;76:751-752.
PubMed

Expression of concern: "The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis" by Ivana Ilic and Tamara Milovanovic [J Hepatol 73 (2020) 701-702].
J Hepatol. 2022;76:758.
PubMed

GUO B, Guo Y, Nima Q, Feng Y, et al
Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
J Hepatol. 2022;76:518-525.
PubMed Abstract available

REIG M, Forner A, Rimola J, Ferrer-Fabrega J, et al
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
J Hepatol. 2022;76:681-693.
PubMed Abstract available

KRONSTEN VT, Tranah TH, Pariante C, Shawcross DL, et al
Gut-derived systemic inflammation as a driver of depression in chronic liver disease.
J Hepatol. 2022;76:665-680.
PubMed Abstract available

RINELLA ME, Dufour JF, Anstee QM, Goodman Z, et al
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
J Hepatol. 2022;76:536-548.
PubMed Abstract available

RATZIU V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
J Hepatol. 2022;76:506-517.
PubMed Abstract available

LUUKKONEN PK, Qadri S, Ahlholm N, Porthan K, et al
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
J Hepatol. 2022;76:526-535.
PubMed Abstract available

YIP TC, Lee HW, Chan WK, Wong GL, et al
Asian perspective on NAFLD-associated HCC.
J Hepatol. 2022;76:726-734.
PubMed Abstract available

February 2022

HUSAIN A, Chiu YT, Sze KM, Ho DW, et al
Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.
J Hepatol. 2022 Feb 25. pii: S0168-8278(22)00125.
PubMed Abstract available

NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00061.
PubMed

WEI CY, Zhu MX, Zhang PF, Huang XY, et al
PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00126.
PubMed Abstract available

MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
PubMed Abstract available

PATIDAR KR, Naved MA, Grama A, Adibuzzaman M, et al
Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00115.
PubMed Abstract available

OLLIVIER-HOURMAND I, Allaire M, Cervoni JP
Management of portal hypertension in patients treated with Atezolizumab and Bevacizumab for hepatocellular carcinoma.
J Hepatol. 2022 Feb 16. pii: S0168-8278(22)00079.
PubMed

SCHEINER B, Pinter M
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy - authors' reply.
J Hepatol. 2022 Feb 14. pii: S0168-8278(22)00073.
PubMed

FONDEVILA MF, Fernandez U, Heras V, Parracho T, et al
Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00077.
PubMed Abstract available

JEONG J, Tanaka M, Iwakiri Y
Hepatic lymphatic vascular system in health and disease.
J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00071.
PubMed Abstract available

MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
PubMed Abstract available

ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
Corrigendum to 'Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence' [J Hepatol 71 (2019) 1152-63].
J Hepatol. 2022 Feb 9. pii: S0168-8278(22)00026.
PubMed

ZINGONI A, Banales JM
PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness.
J Hepatol. 2022 Feb 8. pii: S0168-8278(22)00070.
PubMed

ZENG Q, Klein C, Caruso S, Maille P, et al
Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00031.
PubMed Abstract available

SINGAL AG, Zhang E, Narasimman M, Rich NE, et al
HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
J Hepatol. 2022 Feb 6. pii: S0168-8278(22)00068.
PubMed Abstract available

GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
PubMed Abstract available

JACHS M, Scheiner B, Pinter M
Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
PubMed

ENGELMANN C, Bruns T, Berg T
Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"
J Hepatol. 2022;76:473-475.
PubMed

KIM D, Ahmed A
Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver".
J Hepatol. 2022;76:477-478.
PubMed

FOUAD YM, Mendez-Sanchez N, Zheng MH
One not like the other: The weakness of the blood sugar-MAFLD analogy.
J Hepatol. 2022;76:482-484.
PubMed

DE A, Ahmad N, Mehta M, Singh P, et al
NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.
J Hepatol. 2022;76:475-477.
PubMed

JINDAL A, Sarin SK
G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!
J Hepatol. 2022;76:472-473.
PubMed

WANG YZ
MAFLD supported by 95.45% participants of CSH is NOT representative.
J Hepatol. 2022;76:481-482.
PubMed

BJORNSSON ES, Andrade RJ
Long-term sequelae of drug-induced liver injury.
J Hepatol. 2022;76:435-445.
PubMed Abstract available

DANA J, Debray D, Beaufrere A, Hillaire S, et al
Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
J Hepatol. 2022;76:420-434.
PubMed Abstract available

MALLET V, Parlati L, Martinino A, Scarano Pereira JP, et al
Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
J Hepatol. 2022;76:265-274.
PubMed Abstract available

FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
J Hepatol. 2022;76:446-457.
PubMed Abstract available

January 2022

YANG M, Wu X, Hu J, Wang Y, et al
COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.
J Hepatol. 2022 Jan 28. pii: S0168-8278(22)00022.
PubMed Abstract available

BRUNT EM, Clouston AD, Goodman Z, Guy C, et al
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00024.
PubMed Abstract available

RIDOLA L, Gioia S, Faccioli J, Riggio O, et al
Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.
J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00016.
PubMed

LIMON-MIRO AT, Jackson CD, Eslamparast T, Yamanaka-Okumura H, et al
Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.
J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00018.
PubMed Abstract available

PRADO V, Hernandez-Tejero M, Mucke MM, Marco F, et al
Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.
J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00013.
PubMed Abstract available

BUONOMO E, Mei S, Guinn S, Leo I, et al
Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.
J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00007.
PubMed Abstract available

WONG YJ, Nguyen MH
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
PubMed

ZHOU HF, Yang W, Zhou WZ
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.
J Hepatol. 2022 Jan 18. pii: S0168-8278(22)00004.
PubMed

D'AMICO G, Bernardi M, Angeli P
Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
J Hepatol. 2022 Jan 5. pii: S0168-8278(21)02300.
PubMed

CRAMER T, Vaupel P
Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?
J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02305.
PubMed Abstract available

JAGADISAN B, Dhawan A
Emergencies in Pediatric hepatology.
J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02304.
PubMed Abstract available

MALLET V, Schwarzinger M
Reply to: "Association of chronic liver disease with the prognosis of COVID-19 patients".
J Hepatol. 2022;76:229-230.
PubMed

LONG J, Sang X, Zhao H
Association of chronic liver disease with the prognosis of COVID-19 patients.
J Hepatol. 2022;76:228-229.
PubMed

SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
J Hepatol. 2022;76:211-214.
PubMed

SCHUPPAN D, Myneni S, Surabattula R
Liquid biomarkers for fibrotic NASH - progress in a complex field.
J Hepatol. 2022;76:5-7.
PubMed

Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update".
J Hepatol. 2022;76:251-252.
PubMed

THULUVATH PJ, Li F
Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
J Hepatol. 2022;76:242-243.
PubMed

TURON F, Lisman T, Carlos-Garcia-Pagan J
Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors".
J Hepatol. 2022;76:227-228.
PubMed

LI B, He Q, Lu G, Hong C, et al
Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement.
J Hepatol. 2022;76:225-227.
PubMed

VAN KLEEF LA, Sonneveld MJ, de Man RA, de Knegt RJ, et al
Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.
J Hepatol. 2022;76:245-246.
PubMed

VERMA N, Mehtani R, Duseja A
Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
J Hepatol. 2022;76:241-242.
PubMed

LIU Y, Liu C, Li J, Kim TH, et al
Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102).
J Hepatol. 2022;76:248-250.
PubMed

COREY KE, Pitts R, Lai M, Loureiro J, et al
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
J Hepatol. 2022;76:25-33.
PubMed Abstract available

DA SILVA LIMA N, Fondevila MF, Novoa E, Buque X, et al
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
J Hepatol. 2022;76:11-24.
PubMed Abstract available

VOGEL A, Saborowski A
Medical therapy of HCC.
J Hepatol. 2022;76:208-210.
PubMed

LOOSEN SH, Kostev K, Keitel V, Tacke F, et al
An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD.
J Hepatol. 2022;76:247-248.
PubMed

SINGAL AG, El-Serag HB
Rational HCC screening approaches for patients with NAFLD.
J Hepatol. 2022;76:195-201.
PubMed Abstract available

BJORNSSON HK, Gudbjornsson B, Bjornsson ES
Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
J Hepatol. 2022;76:86-92.
PubMed Abstract available

SEKIBA K, Otsuka M, Funato K, Miyakawa Y, et al
HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA.
J Hepatol. 2022;76:53-62.
PubMed Abstract available

ZHANG IW, Curto A, Lopez-Vicario C, Casulleras M, et al
Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure.
J Hepatol. 2022;76:93-106.
PubMed Abstract available

GHELFI J, Brusset B, Thony F, Decaens T, et al
Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.
J Hepatol. 2022;76:216-218.
PubMed

December 2021

SCHEINER B, Pinter M
Letter to the Editor: Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? - authors' reply.
J Hepatol. 2021 Dec 31. pii: S0168-8278(21)02302.
PubMed

DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
Baveno VII - Renewing consensus in portal hypertension.
J Hepatol. 2021 Dec 30. pii: S0168-8278(21)02299.
PubMed Abstract available

BELLI LS, Perricone G, Jalan R
Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
PubMed

WANG H, Zhang S, Zhang Y, Jia J, et al
Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].
J Hepatol. 2021 Dec 26. pii: S0168-8278(21)02248.
PubMed

GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
PubMed Abstract available

SOUNDARARAJAN R, Gupta P
Reply to "Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead".
J Hepatol. 2021 Dec 23. pii: S0168-8278(21)02292.
PubMed

BEAUMONT E, Larochette V, Preisser L, Miot C, et al
IL-26 inhibits hepatitis C virus replication in hepatocytes.
J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
PubMed Abstract available

TEY SK, Wong SWK, Tung Chan JY, Mao X, et al
Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.
J Hepatol. 2021 Dec 16. pii: S0168-8278(21)02245.
PubMed Abstract available

WANG X, Zeldin S, Shi H, Zhu C, et al
TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02242.
PubMed Abstract available

CHENG AL, Qin S, Ikeda M, Galle PR, et al
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02241.
PubMed Abstract available

CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
PubMed

KASSIANIDES C, Dusheiko G, Di Bisceglie A, Hoofnagle JH, et al
Michael Charles Kew - Frontrunner in Hepatology.
J Hepatol. 2021 Dec 6. pii: S0168-8278(21)02224.
PubMed

KADONO K, Kageyama S, Nakamura K, Hirao H, et al
Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.
J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02235.
PubMed Abstract available

NACHIT M, Kwanten WJ, Francque S
Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?"
J Hepatol. 2021;75:1513-1514.
PubMed

LUEDDE T, Baumann U, Keitel V
Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD".
J Hepatol. 2021;75:1502-1503.
PubMed

WONG VW, Lazarus JV
Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.
J Hepatol. 2021;75:1267-1270.
PubMed

POHL J, Gebauer B, Gebert P, Tacke F, et al
Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score - back to basics?
J Hepatol. 2021;75:1505-1506.
PubMed

MATTHEWS C, Cross TJS
Before we can find an evidence base for HCC surveillance, we need to define our target demographic.
J Hepatol. 2021;75:1494-1495.
PubMed

KOTHA S, Berry P
Multiple investigations for a very common disorder: Finding the right balance in NAFLD.
J Hepatol. 2021;75:1501-1502.
PubMed

CADENAS-SANCHEZ C, Idoate F, Villanueva A, Cabeza R, et al
Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?
J Hepatol. 2021;75:1511-1513.
PubMed

NIELSEN MJ, Leeming DJ, Goodman Z, Friedman S, et al
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
J Hepatol. 2021;75:1292-1300.
PubMed Abstract available

IOANNOU GN
Epidemiology and risk-stratification of NAFLD-associated HCC.
J Hepatol. 2021;75:1476-1484.
PubMed Abstract available

YANG T, Poenisch M, Khanal R, Hu Q, et al
Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
J Hepatol. 2021;75:1420-1433.
PubMed Abstract available

HSU CL, Duan Y, Fouts DE, Schnabl B, et al
Intestinal virome and therapeutic potential of bacteriophages in liver disease.
J Hepatol. 2021;75:1465-1475.
PubMed Abstract available

KIM D, Konyn P, Sandhu KK, Dennis BB, et al
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
J Hepatol. 2021;75:1284-1291.
PubMed Abstract available

ENGELMANN C, Herber A, Franke A, Bruns T, et al
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).
J Hepatol. 2021;75:1346-1354.
PubMed Abstract available

GADALETA RM, Moschetta A
Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
J Hepatol. 2021;75:1440-1451.
PubMed Abstract available

D'AMICO G, Maruzzelli L, Airoldi A, Petridis I, et al
Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.
J Hepatol. 2021;75:1355-1366.
PubMed Abstract available

November 2021

CABIBBO G, Singal AG
The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma.
J Hepatol. 2021 Nov 26. pii: S0168-8278(21)02226.
PubMed

LIU Y, Zhuo S, Zhou Y, Ma L, et al
Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02182.
PubMed Abstract available

D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
PubMed Abstract available

SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
PubMed Abstract available

DING GY, Ma JQ, Yun JP, Chen X, et al
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
PubMed Abstract available

TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
PubMed Abstract available

HUO TI, Liao JI, Ho SY
Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?
J Hepatol. 2021 Nov 12. pii: S0168-8278(21)02176.
PubMed

XU X, Nan Y
Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
J Hepatol. 2021 Nov 11. pii: S0168-8278(21)02170.
PubMed

RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
PubMed Abstract available

PAVLIDES M, Francis S, Barnes E
Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
PubMed

COLOMBO M, Barouki R
Expanding the liver exposome: should hepatologists care about air pollution?
J Hepatol. 2021 Nov 5. pii: S0168-8278(21)02165.
PubMed

SANGRO B, Bruix J, Chan SL, Galle PR, et al
Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
PubMed

HAN Y, Black S, Gong Z, Chen Z, et al
Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
PubMed Abstract available

PAPATHEODORIDI M, Pinzani M, Tsochatzis E
Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!"
J Hepatol. 2021;75:1247.
PubMed

GUPTA P, Sharma V, Kalra N
Reply to: "Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening".
J Hepatol. 2021;75:1259-1260.
PubMed

VILLANUEVA C, Bosch J
Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?"
J Hepatol. 2021;75:1242-1243.
PubMed

KUTAIBA N, Ardalan Z
Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening.
J Hepatol. 2021;75:1258-1259.
PubMed

JI Y, Li J, He Q, Zhou L, et al
Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.
J Hepatol. 2021;75:1243-1245.
PubMed

CRISTOFERI L, Nardi A, Carbone M
Transient elastography in chronic liver disease: Beware of the cut-offs!
J Hepatol. 2021;75:1245-1246.
PubMed

REICHERT MC, Ripoll C
First things first! Can bacterial infections be considered as decompensating events per se?
J Hepatol. 2021;75:1241-1242.
PubMed

LANGE NF, Radu P, Dufour JF
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
J Hepatol. 2021;75:1217-1227.
PubMed Abstract available

HAGSTROM H, Simon TG, Roelstraete B, Stephansson O, et al
Maternal obesity increases the risk and severity of NAFLD in offspring.
J Hepatol. 2021;75:1042-1048.
PubMed Abstract available

RUIZ-BLAZQUEZ P, Pistorio V, Fernandez-Fernandez M, Moles A, et al
The multifaceted role of cathepsins in liver disease.
J Hepatol. 2021;75:1192-1202.
PubMed Abstract available

SIMON TG, Roelstraete B, Hartjes K, Shah U, et al
Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
J Hepatol. 2021;75:1034-1041.
PubMed Abstract available

WANG Q, Liang N, Yang T, Li Y, et al
DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.
J Hepatol. 2021;75:1142-1153.
PubMed Abstract available

JALAN R, Gustot T, Fernandez J, Bernal W, et al
'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.
J Hepatol. 2021;75:1228-1235.
PubMed Abstract available

FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
J Hepatol. 2021;75:1154-1163.
PubMed Abstract available

RASMUSSEN DN, Thiele M, Johansen S, Kjaergaard M, et al
Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
J Hepatol. 2021;75:1017-1025.
PubMed Abstract available

LI F, Thuluvath PJ
EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.
J Hepatol. 2021;75:1096-1103.
PubMed Abstract available

October 2021

CHAO X, Wang S, Fulte S, Ma X, et al
Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.
J Hepatol. 2021 Oct 25. pii: S0168-8278(21)02151.
PubMed Abstract available

LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
PubMed Abstract available

LAN T, Hu Y, Hu F, Li H, et al
Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02105.
PubMed Abstract available

WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
PubMed Abstract available

QING J, Ren Y, Zhang Y, Yan M, et al
Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
PubMed Abstract available

SCHEINER B, Pomej K, Kirstein MM, Hucke F, et al
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02100.
PubMed Abstract available

SEN P, Qadri S, Luukkonen PK, Ragnarsdottir O, et al
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
J Hepatol. 2021 Oct 7. pii: S0168-8278(21)02104.
PubMed Abstract available

PINYOL R, Torrecilla S, Wang H, Montironi C, et al
Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
J Hepatol. 2021 Oct 6. pii: S0168-8278(21)02044.
PubMed

BEAUFRERE A, Caruso S, Calderaro J, Pote N, et al
Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.
J Hepatol. 2021 Oct 5. pii: S0168-8278(21)02099.
PubMed Abstract available

KIM HY, Lampertico P, Nam JY, Lee HC, et al
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
PubMed Abstract available

BAFFY G, Bosch J
Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
PubMed Abstract available

WONG F, Piano S, Angeli P
Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
J Hepatol. 2021;75:1010-1012.
PubMed

FENG MW, Hanley KL, Feng GS
Androgen receptor, neovascularization and liver cancer metastasis.
J Hepatol. 2021;75:768-769.
PubMed

LIN S, Agarwal B, Kumar R, Jalan R, et al
Defining the prognosis of critically ill patients with alcohol-related liver disease.
J Hepatol. 2021;75:986-987.
PubMed

FISCHER P, Stefanescu H, Hategan R, Procopet B, et al
Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!
J Hepatol. 2021;75:1009-1010.
PubMed

FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
J Hepatol. 2021;75:935-959.
PubMed Abstract available

CHEN X, Chen S, Pang J, Tang Y, et al
Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?
J Hepatol. 2021;75:987-989.
PubMed

LACKNER C, Stauber RE, Davies S, Denk H, et al
Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.
J Hepatol. 2021;75:810-819.
PubMed Abstract available

YOUNES R, Caviglia GP, Govaere O, Rosso C, et al
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
J Hepatol. 2021;75:786-794.
PubMed Abstract available

GOLABI P, Paik JM, AlQahtani S, Younossi Y, et al
Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
J Hepatol. 2021;75:795-809.
PubMed Abstract available

SELVARAJ EA, Mozes FE, Jayaswal ANA, Zafarmand MH, et al
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
J Hepatol. 2021;75:770-785.
PubMed Abstract available

September 2021

GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
PubMed

HSIEH J, Molusky MM, McCabe KM, Fotakis P, et al
TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02083.
PubMed Abstract available

GRONEBERG M, Hoenow S, Marggraff C, Fehling H, et al
HIF-1alpha modulates sex-specific Th17/Treg responses during hepatic amoebiasis.
J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02082.
PubMed Abstract available

D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
PubMed Abstract available

CHOI WM, Yip TC, Lim YS, Wong GL, et al
Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
PubMed Abstract available

PATEL V, Lee S, McPhail M, Da Silva K, et al
Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
PubMed Abstract available

KIM HS, Yu X, Kramer J, Thrift AP, et al
Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
PubMed Abstract available

ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
PubMed

JUANOLA A, Graupera I, Elia C, Piano S, et al
Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
PubMed Abstract available

CHEN Q, Wang H, Li Z, Li F, et al
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
PubMed Abstract available

DAI CY, Yeh ML, Yu ML
An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
PubMed

VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
PubMed Abstract available

DING ZY, Li GX, Shu C, Yin P, et al
Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
J Hepatol. 2021;75:742-744.
PubMed

LUO MS, Huang GJ
Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
J Hepatol. 2021;75:737-739.
PubMed

SINGH A, Premkumar M, Singh V
Liver injury in COVID-19 - The culprit may not be COVID-19!
J Hepatol. 2021;75:739-740.
PubMed

MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
J Hepatol. 2021;75:647-658.
PubMed Abstract available

WANG Q, Bai W, Han G
Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
J Hepatol. 2021;75:747-749.
PubMed

BETTINGER D, Thimme R, Schultheiss M
Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
J Hepatol. 2021;75:749-750.
PubMed

PAPATHEODORIDI M, Pinzani M, Tsochatzis E
Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
J Hepatol. 2021;75:752-753.
PubMed

PARK H, Yoon EL, Cho S, Nah EH, et al
Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
J Hepatol. 2021;75:725-726.
PubMed

MA L, Craig AJ, Heinrich S
Hypoxia is a key regulator in liver cancer progression.
J Hepatol. 2021;75:736-737.
PubMed

KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
External validation of the Freiburg index of post-TIPS survival.
J Hepatol. 2021;75:746-747.
PubMed

GENESCA J, Abraldes JG, Bosch J
Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
J Hepatol. 2021;75:750-752.
PubMed

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.
J Hepatol. 2021;75:659-689.
PubMed Abstract available

YOO T, Joo SK, Kim HJ, Kim HY, et al
Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
J Hepatol. 2021;75:514-523.
PubMed Abstract available

CORRADINI E, Buzzetti E, Dongiovanni P, Scarlini S, et al
Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
J Hepatol. 2021;75:506-513.
PubMed Abstract available

August 2021

WANG H, Zhang S, Zhang Y, Jia J, et al
TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
PubMed Abstract available

DAI CY, Chuang WL, Yu ML
A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
PubMed

RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
PubMed Abstract available

THULUVATH PJ, Robarts P, Chauhan M
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
PubMed Abstract available

BLOOM P, Tapper EB, Young VB, Lok AS, et al
Microbiome Therapeutics for Hepatic Encephalopathy.
J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
PubMed Abstract available

WANG H, Zhang H, Wang Y, Brown ZJ, et al
Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
PubMed Abstract available

WANG J, Hou Z, Liu J, Gu Y, et al
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
J Hepatol. 2021;75:439-441.
PubMed Abstract available

NACHIT M, Kwanten WJ, Thissen JP, Op De Beeck B, et al
Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
J Hepatol. 2021;75:292-301.
PubMed Abstract available

TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
J Hepatol. 2021;75:424-434.
PubMed Abstract available

ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
J Hepatol. 2021;75:333-341.
PubMed Abstract available

MARTINEZ J, Hernandez-Gea V, Rodriguez-de-Santiago E, Tellez L, et al
Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.
J Hepatol. 2021;75:342-350.
PubMed Abstract available

YANG Y, Sangwung P, Kondo R, Jung Y, et al
Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
J Hepatol. 2021;75:377-386.
PubMed Abstract available

July 2021

TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
PubMed Abstract available

TURON F, Driever EG, Baiges A, Cerda E, et al
Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
PubMed Abstract available

CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
PubMed Abstract available

GALLE PR, Abou-Alfa G
Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
PubMed

SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
PubMed

BRISSOT P, Loreal O
Hemochromatoses.
J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
PubMed

BRUIX J, Chan SL, Galle PR, Rimassa L, et al
Systemic treatment of hepatocellular carcinoma. An EASL position paper.
J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
PubMed Abstract available

VAQUERO J, Keitel V
Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
PubMed

CLARIA J, Curto A, Moreau R, Colsch B, et al
Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
PubMed Abstract available

ZHU C, Boucheron N, Muller AC, Majek P, et al
24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
PubMed Abstract available

BETTINGER D, Thimme R, Schultheiss M
Reply: TIPS and liver transplantation should always be discussed together.
J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
PubMed

SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
Polyploidy control in hepatic health and disease.
J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
PubMed Abstract available

ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
PubMed

VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
J Hepatol. 2021;75 Suppl 1:S82-S100.
PubMed Abstract available

TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
The microbiota in cirrhosis and its role in hepatic decompensation.
J Hepatol. 2021;75 Suppl 1:S67-S81.
PubMed Abstract available

ENGELMANN C, Claria J, Szabo G, Bosch J, et al
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
J Hepatol. 2021;75 Suppl 1:S49-S66.
PubMed Abstract available

JEPSEN P, Younossi ZM
The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
J Hepatol. 2021;75 Suppl 1:S3-S13.
PubMed Abstract available

TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
Sarcopenia and frailty in decompensated cirrhosis.
J Hepatol. 2021;75 Suppl 1:S147-S162.
PubMed Abstract available

JALAN R, D'Amico G, Trebicka J, Moreau R, et al
New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
J Hepatol. 2021;75 Suppl 1:S14-S26.
PubMed Abstract available

GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
Management of the major complications of cirrhosis: Beyond guidelines.
J Hepatol. 2021;75 Suppl 1:S135-S146.
PubMed Abstract available

CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
J Hepatol. 2021;75 Suppl 1:S118-S134.
PubMed Abstract available

FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
J Hepatol. 2021;75 Suppl 1:S101-S117.
PubMed Abstract available

JALAN R, Szabo G
New concepts and perspectives in decompensated cirrhosis.
J Hepatol. 2021;75 Suppl 1:S1-S2.
PubMed

KREMOSER C
FXR agonists for NASH: How are they different and what difference do they make?
J Hepatol. 2021;75:12-15.
PubMed

LIU Y, Xu N, Ji H
Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
J Hepatol. 2021;75:241-243.
PubMed

BOSCH J
Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target".
J Hepatol. 2021;75:248-249.
PubMed

STAUBER RE, Scharnagl H, Marsche G
Reply to: "Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF".
J Hepatol. 2021;75:245-246.
PubMed

SIMBRUNNER B, Costa D, Reiberger T
Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease".
J Hepatol. 2021;75:234-236.
PubMed

XU L, Wettschureck N, Bai Y, Yuan Z, et al
Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
J Hepatol. 2021;75:238-241.
PubMed

WEN X, Tong J, Yao M, Hu J, et al
Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF.
J Hepatol. 2021;75:243-245.
PubMed

WANG X, Luo X, Yang L
Achieving an effective pressure reduction after TIPS: The need for a new target.
J Hepatol. 2021;75:246-248.
PubMed

FERRARESE A, Plebani M, Frigo AC, Burra P, et al
Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
J Hepatol. 2021;75:232-234.
PubMed

BEUERS U
EASL recognition award recipient 2021: Prof. Dieter Haussinger.
J Hepatol. 2021;75:7-9.
PubMed

ROMERO-GOMEZ M
EASL international recognition award recipient 2021: Prof. Dr. Nahum Mendez-Sanchez.
J Hepatol. 2021;75:10-11.
PubMed

MENDEZ-SANCHEZ N, Diaz-Orozco L, Cordova-Gallardo J
Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.
J Hepatol. 2021;75:221-222.
PubMed

PETERS L, Burkert S, Gruner B
Parasites of the liver - epidemiology, diagnosis and clinical management in the European context.
J Hepatol. 2021;75:202-218.
PubMed Abstract available

SIMON J, Goikoetxea-Usandizaga N, Serrano-Macia M, Fernandez-Ramos D, et al
Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.
J Hepatol. 2021;75:34-45.
PubMed Abstract available

LIU C, Zhou B, Meng M, Zhao W, et al
FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
J Hepatol. 2021;75:150-162.
PubMed Abstract available

STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
J Hepatol. 2021;75:86-97.
PubMed Abstract available

GUSTOT T, Stadlbauer V, Laleman W, Alessandria C, et al
Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.
J Hepatol. 2021;75 Suppl 1:S36-S48.
PubMed Abstract available

MOREAU R, Gao B, Papp M, Banares R, et al
Acute-on-chronic liver failure: A distinct clinical syndrome.
J Hepatol. 2021;75 Suppl 1:S27-S35.
PubMed Abstract available

BURRA P, Samuel D, Sundaram V, Duvoux C, et al
Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
J Hepatol. 2021;75 Suppl 1:S178-S190.
PubMed Abstract available

BERNAL W, Karvellas C, Saliba F, Saner FH, et al
Intensive care management of acute-on-chronic liver failure.
J Hepatol. 2021;75 Suppl 1:S163-S177.
PubMed Abstract available

June 2021

MA L, Wang L, Khatib SA, Chang CW, et al
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
PubMed Abstract available

VITHAYATHIL M, Bridegwater J, Khan SA
Medical therapies for intra-hepatic cholangiocarcinoma.
J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
PubMed

QUITT O, Luo S, Meyer M, Xie Z, et al
T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
PubMed Abstract available

D'AMICO G, Bernardi M, Angeli P
TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
PubMed Abstract available

BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
PubMed Abstract available

GEIDL-FLUECK B, Gerber PA
Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
PubMed

SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
PubMed

WU J, Li H, Xu Z, Ran L, et al
Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
PubMed

CORPECHOT C
Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
PubMed

FLEMMING JA, Velez MP
The ART of medicine: Counselling women with liver disease about assisted reproductive technology.
J Hepatol. 2021;74:1283-1285.
PubMed

KUMAR R, Jalan R
Reply to: "Failure to control variceal bleeding: Definition matters".
J Hepatol. 2021;74:1492-1493.
PubMed

BAIGES A, Bureau C, Garcia-Pagan JC
Failure to control variceal bleeding: Definition matters.
J Hepatol. 2021;74:1491-1492.
PubMed

BERNAL W, McPhail MJ
Acute liver failure.
J Hepatol. 2021;74:1489-1490.
PubMed

GILGENKRANTZ H, Mallat A, Moreau R, Lotersztajn S, et al
Targeting cell-intrinsic metabolism for antifibrotic therapy.
J Hepatol. 2021;74:1442-1454.
PubMed Abstract available

BRUIX J
Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot.
J Hepatol. 2021;74:1483-1488.
PubMed Abstract available

BETTINGER D, Sturm L, Pfaff L, Hahn F, et al
Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
J Hepatol. 2021;74:1362-1372.
PubMed Abstract available

CADOUX M, Caruso S, Pham S, Gougelet A, et al
Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness.
J Hepatol. 2021;74:1386-1397.
PubMed Abstract available

WEI G, Cao J, Huang P, An P, et al
Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
J Hepatol. 2021;74:1416-1428.
PubMed Abstract available

ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
J Hepatol. 2021;74:1355-1361.
PubMed Abstract available

May 2021

KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
PubMed Abstract available

RUDLER M, Savier E, Alioua I, Sultanik P, et al
TIPS and liver transplantation should always be discussed together.
J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
PubMed

BAUMERT TF
"We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
PubMed

CORNBERG M, Eberhardt CS
Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
PubMed

CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
PubMed Abstract available

WANG H, Wen B, Chen J
"Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
PubMed

NAN Y, An J, Bao J, Chen H, et al
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
PubMed Abstract available

ZHOU HC, Liu CX, Pan WD, Shang LR, et al
Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
PubMed Abstract available

PINYOL R, Torrecilla S, Wang H, Montironi C, et al
Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
PubMed Abstract available

TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
PubMed

KUDO M, Matilla A, Santoro A, Melero I, et al
CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
PubMed Abstract available

ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
PubMed Abstract available

YEO YH, Hwang J, Jeong D, Dang N, et al
Surveillance of patients with cirrhosis remains suboptimal in the United States.
J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
PubMed Abstract available

HYUN J, Al Abo M, Dutta RK, Oh SH, et al
Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
PubMed Abstract available

CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
PubMed Abstract available

JOHNSON PJ
In search of an evidence base for HCC surveillance: Purity or pragmatism?
J Hepatol. 2021;74:1025-1027.
PubMed

ARROYO V, Fernandez J, Moreau R
Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome".
J Hepatol. 2021;74:1265-1267.
PubMed

COENRAAD MJ, Artru F
Amino acids in acute-on-chronic liver failure: Another piece of the puzzle?
J Hepatol. 2021;74:1015-1017.
PubMed

ESLAM M, George J
MAFLD: Now is the time to capitalize on the momentum.
J Hepatol. 2021;74:1262-1263.
PubMed

FOUAD Y, Gomaa A, Semida N, Ghany WA, et al
Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.
J Hepatol. 2021;74:1254-1256.
PubMed

ALEM SA, Gaber Y, Abdalla M, Said E, et al
Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback.
J Hepatol. 2021;74:1261-1262.
PubMed

KASPER P, Martin A, Lang S, Demir M, et al
Hypertension in NAFLD: An uncontrolled burden.
J Hepatol. 2021;74:1258-1260.
PubMed

SPEARMAN CW, Desalegn H, Ocama P, Awuku YA, et al
The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
J Hepatol. 2021;74:1256-1258.
PubMed

ZHANG Y, Lu Z, Zeng W, Zhao J, et al
Two sides of NNMT in alcoholic and non-alcoholic fatty liver development.
J Hepatol. 2021;74:1250-1253.
PubMed

ZACCHERINI G, Aguilar F, Caraceni P, Claria J, et al
Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.
J Hepatol. 2021;74:1117-1131.
PubMed Abstract available

WANG T, Chen K, Yao W, Zheng R, et al
Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.
J Hepatol. 2021;74:1038-1052.
PubMed Abstract available

April 2021

IZZY M, Lin G, Watt KD
Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
PubMed

SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
Current knowledge and management of portal vein thrombosis in cirrhosis.
J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
PubMed Abstract available

BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
PubMed

VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
PubMed Abstract available

BELLI LS, Duvoux C, Artzner T, Bernal W, et al
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00261.
PubMed Abstract available

GINES P
Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
PubMed

TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
Falls are common, morbid, and predictable in patients with cirrhosis.
J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
PubMed Abstract available

OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
PubMed Abstract available

TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
PubMed Abstract available

GOLSE N, Vibert E, Vignon-Clementel IE
Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
PubMed

SUNDARAM V
Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
PubMed

CRAMER T, Vaupel P
Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
PubMed

PRINZ P
Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
PubMed

DESSEIN A
Clinical utility of polygenic risk scores for predicting NAFLD disorders.
J Hepatol. 2021;74:769-770.
PubMed

COSTA D, Simbrunner B, Reiberger T
Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease".
J Hepatol. 2021;74:1000-1001.
PubMed

HOBEIKA C, Fuks D
Reply to: "Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
J Hepatol. 2021;74:987-988.
PubMed

HEGARTY R, Singh S, Bansal S, Fitzpatrick E, et al
NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.
J Hepatol. 2021;74:991-992.
PubMed

ESLAM M, Ratziu V, George J
Yet more evidence that MAFLD is more than a name change.
J Hepatol. 2021;74:977-979.
PubMed

ESLAM M, George J
MAFLD: A holistic view to redefining fatty liver disease.
J Hepatol. 2021;74:983-985.
PubMed

ESLAM M, George J
MAFLD: A game changer redefining fatty liver disease for adults and children.
J Hepatol. 2021;74:992-994.
PubMed

AMPUERO J, Gallego-Duran R, Romero-Gomez M
Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
J Hepatol. 2021;74:971-972.
PubMed

ZHENG KI, Sun DQ, Jin Y, Zhu PW, et al
Clinical utility of the MAFLD definition.
J Hepatol. 2021;74:989-991.
PubMed

DEBNATH P, Rathi P
Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease.
J Hepatol. 2021;74:999-1000.
PubMed

MORENO C, Sheron N, Tiniakos D, Lackner C, et al
"Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls.
J Hepatol. 2021;74:979-982.
PubMed

BAFFY G
Is the name 'NAFLD' too big to fail? Let's keep it for 'nutrition-associated fatty liver disease'.
J Hepatol. 2021;74:988.
PubMed

XIA M, Zeng H, Wang S, Tang H, et al
Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling.
J Hepatol. 2021;74:974-977.
PubMed

LIU M, Sun L, Mao Y
The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
J Hepatol. 2021;74:970-971.
PubMed

SINGH SP, Anirvan P, Reddy KR, Conjeevaram HS, et al
Non-alcoholic fatty liver disease: Not time for an obituary just yet!
J Hepatol. 2021;74:972-974.
PubMed

PONIACHIK J, Roblero JP, Urzua A, Cattaneo M, et al
A new definition for non-alcoholic fatty liver disease.
J Hepatol. 2021;74:982-983.
PubMed

RUSSOLILLO N, Aldrighetti L, Guglielmi A, Giuliante F, et al
Correspondence on "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
J Hepatol. 2021;74:985-986.
PubMed

RIMASSA L, Personeni N, Czauderna C, Foerster F, et al
Systemic treatment of HCC in special populations.
J Hepatol. 2021;74:931-943.
PubMed Abstract available

COSTA D, Simbrunner B, Jachs M, Hartl L, et al
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
J Hepatol. 2021;74:819-828.
PubMed Abstract available

March 2021

MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
PubMed Abstract available

LI J, Zhu X, Zhang M, Zhang Y, et al
Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
PubMed Abstract available

LUJAMBIO A, Maina F
Turning up our understanding of liver cancer by a notch.
J Hepatol. 2021;74:502-504.
PubMed

JOYE R, Lador F, Aggoun Y, Farhat N, et al
Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
J Hepatol. 2021;74:742-747.
PubMed Abstract available

HEINRICH S, Craig AJ, Ma L, Heinrich B, et al
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
J Hepatol. 2021;74:700-715.
PubMed Abstract available

MOZZANEGA B
Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
J Hepatol. 2021;74:750-751.
PubMed

CHAND D, Mohr F, McMillan H, Tukov FF, et al
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
J Hepatol. 2021;74:560-566.
PubMed Abstract available

MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
J Hepatol. 2021;74:593-602.
PubMed Abstract available

February 2021

SHAHINI E, Ahmed F
Chronic fatigue should not be overlooked in primary biliary cholangitis.
J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
PubMed

GUDD CL, Au L, Triantafyllou E, Shum B, et al
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
PubMed Abstract available

MALLET V
Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
PubMed

BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
PubMed

RIPOLL C, Zipprich A
Open or closed window: That is the question.
J Hepatol. 2021;74:485-486.
PubMed

ANAND A, Kumar R, Shalimar
PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
J Hepatol. 2021;74:478-479.
PubMed

HERNAEZ R, Kanwal F
Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".
J Hepatol. 2021;74:477.
PubMed

GOUDSMIT BFJ, Tushuizen ME, Putter H, Braat AE, et al
The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.
J Hepatol. 2021;74:475-476.
PubMed

MANCO R, Itzkovitz S
Liver zonation.
J Hepatol. 2021;74:466-468.
PubMed

SAWATZKI M, Guller U, Gusewell S, Husarik DB, et al
Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.
J Hepatol. 2021;74:419-427.
PubMed Abstract available

WINKLER M, Staniczek T, Kurschner SW, Schmid CD, et al
Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.
J Hepatol. 2021;74:380-393.
PubMed Abstract available

WONG F, Piano S, Singh V, Bartoletti M, et al
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure.
J Hepatol. 2021;74:330-339.
PubMed Abstract available

January 2021

CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
PubMed Abstract available

SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
PubMed Abstract available

RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
PubMed Abstract available

RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
PubMed Abstract available

FORLANO R, Mullish BH, Maurice JB, Thursz MR, et al
NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials.
J Hepatol. 2021;74:241-242.
PubMed

WU Y, Kumar R, Huang J, Wang M, et al
FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
J Hepatol. 2021;74:247-248.
PubMed

NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
Challenges in understanding the consequences of variants in ABCB4 gene.
J Hepatol. 2021;74:242-243.
PubMed

TSOCHATZIS EA, Srivastava A, Rosenberg W
Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".
J Hepatol. 2021;74:248-249.
PubMed

SAVALE L, Sitbon O
Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
J Hepatol. 2021;74:238-239.
PubMed

KOLHE K, Tripathi DM, Kaur S
Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?
J Hepatol. 2021;74:237-238.
PubMed

STATTERMAYER AF, Ferenci P, Trauner M
Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
J Hepatol. 2021;74:244-245.
PubMed

COZMESCU AC, Counsell J, Gissen P
Gene therapies targeting the liver.
J Hepatol. 2021;74:235-236.
PubMed

BOSCH J
Small diameter shunts should lead to safe expansion of the use of TIPS.
J Hepatol. 2021;74:230-234.
PubMed Abstract available

DWYER BJ, Macmillan MT, Brennan PN, Forbes SJ, et al
Cell therapy for advanced liver diseases: Repair or rebuild.
J Hepatol. 2021;74:185-199.
PubMed Abstract available

TEO K, Abeysekera KWM, Adams L, Aigner E, et al
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.
J Hepatol. 2021;74:20-30.
PubMed Abstract available

October 2020

CARBONE M, Ronca V, Invernizzi P
Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
PubMed

HYDES T, Khakoo SI
A spotlight on natural killer cells in primary biliary cholangitis.
J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
PubMed

September 2020

HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
PubMed Abstract available

LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
PubMed Abstract available

August 2020

YOSHIZUMI T, Itoh S, Shimokawa M, Inokuchi S, et al
Simultaneous splenectomy improves outcomes after adult living donor liver transplantation.
J Hepatol. 2020 Aug 19. pii: S0168-8278(20)30547.
PubMed Abstract available

LINE PD, Dueland S
Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence.
J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30539.
PubMed

July 2020

DEEB M, Karlsen TH, Hirschfield GM
The 6 C's of Primary Sclerosing Cholangitis.
J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
PubMed

May 2020

GULFO J, Rotondo F, de Leon CGA, Cornide-Petronio ME, et al
FGF15 improves outcomes after brain dead donor liver transplantation with steatotic and non-steatotic grafts in rats.
J Hepatol. 2020 May 15. pii: S0168-8278(20)30299.
PubMed Abstract available

STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
PubMed Abstract available

April 2020

CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
PubMed Abstract available

March 2020

CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
PubMed Abstract available

KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
PubMed Abstract available

HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
PubMed Abstract available

SAVALE L, Guimas M, Ebstein N, Fertin M, et al
Portopulmonary hypertension in the current era of pulmonary hypertension management.
J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
PubMed Abstract available

February 2020

VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
Genotype correlates with the natural history of severe bile salt export pump deficiency.
J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
PubMed Abstract available

MULLER M, Bird TG, Nault JC
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
PubMed Abstract available

January 2020

BAJAJ JS, Khoruts A
Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
PubMed Abstract available

PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
PubMed Abstract available

BASSEGODA O, Huelin P, Ariza X, Sole C, et al
DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
PubMed Abstract available

December 2019

PAISANT A, Vilgrain V, Riou J, Oberti F, et al
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
PubMed Abstract available

GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
PubMed Abstract available

SHE S, Wu X, Zheng D, Pei X, et al
PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
PubMed Abstract available

November 2019

CHIEW AL, James LP, Isbister GK, Pickering JW, et al
Early Acetaminophen-Protein Adducts Predict Hepatotoxicity Following Overdose.
J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30677.
PubMed Abstract available

HE X, Wang Y, Fan X, Lei N, et al
A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
PubMed Abstract available

October 2019

SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
PubMed Abstract available

GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
PubMed Abstract available

BRIL F, Barb D, Lomonaco R, Lai J, et al
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.